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Summary: 
The development of human hepatocellular carcinoma (HCC) is a complex process. 
Recently it has been shown that the synergy of transforming growth factor (TGF)-β with 
constitutive active Ras induces an epithelial-to-mesenchymal transition (EMT) of murine 
hepatocytes. This phenotypical change of tumor cells results in increased malignancy, a 
higher migratory potential and metastasis. The loss of E-cadherin, which represents an 
essential constitutive factor for the formation of adherens junctions, is a key event in 
EMT. In recent studies, a novel key regulator of malignant epithelial cells, referred to as 
interleukin like EMT inducer (ILEI), was identified by expression profiling of epithelial 
versus fibroblastoid breast cancer cells. To understand the role of ILEI in hepatocellular 
carcinoma we employed p19ARF deficient hepatocytes to study whether ILEI alone or in 
combination with oncogenic H-Ras is able to induce and maintain EMT. The role of ILEI 
on tumor formation was analyzed by injection of ILEI overexpressing cells subcutanously 
in severe combined immunodeficient (SCID) mice. In further experiments an 
upregulation of components of the PDGF-signalling pathway was detectable. In addition 
an increase in activated Stat3 and nuclear β-catenin accumulation was observed in 
tumors derived from ILEI overexpressing cells. A human tissue array consisting of 69 
patient samples was further used to analyze the distribution of ILEI in primary human 
HCC and revealed a strong cytoplasmic expression particularly in poorly differentiated 
tumors. In conclusion the obtained results indicate that ILEI requires oncogenic Ras to 
induce EMT via mechanisms involving PDGF-R/β-catenin and PDGF-R/Stat3 signaling. 
A further project focused on the role of activated Stat3 during EMT formation of 
neoplastic hepatocytes. In this study, the cooperative function of Stat3, oncogenic H-Ras 
and TGFβ1 was analyzed using the same cellular model of p19ARF null hepatocytic cells. 
Constitutive active (ca) and dominant negative (dn) mutants of Stat3 were introduced 
into hepatocytes and the ability to form tumors and metastasis was analyzed. These 
experiments revealed a tumor suppressive role of Stat3 together with H-Ras and p19ARF 
deletion in liver carcinogenesis. Expression profiling showed an upregulation of c-jun 
and MMP-3, which have been reported to play an important role in the establishment of 
EMT. Together, these results suggest a crucial function of Stat3 in combination with 
oncogenic Ras and TGFβ during hepatocellular tumor progression. 
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Zusammenfassung: 
Die Entwicklung hepatozellulärer Karzinome ist ein komplexer Vorgang. Kürzlich wurde 
beschrieben, dass die Kooperation von Signalkaskaden, wie etwa „Transforming Growth 
Factor (TGF)-β“ und onkogenem H-Ras einen Prozess der „Epithelial-to-Mesenchymal 
Transition (EMT)“ induziert, der eine Zunahme der Malignität bewirkt. Diese 
Veränderung von epithelialen zu fibroblastoiden Zellen geht mit einem erhöhten 
Migrationspotenzial einher und bewirkt eine Metastasenbildung. Der Verlust von E-
Cadherin, eines für die Ausbildung der Zell-Zell-Kontakte wichtiges Protein, nimmt in der 
EMT eine entscheidende Rolle ein. Durch „Expression Profiling“ von epithelialen versus 
mesenchymalen Brustkrebszellen wurde ein bisweilen unbekanntes Protein, genannt 
ILEI, identifiziert, das eine EMT induzieren kann. Um die Eigenschaften dieses neuen 
Proteins während der hepatozellulären Kanzerogenese zu untersuchen, wurde ILEI in 
p19ARF-defizienten Hepatozyten entweder alleine oder in Kooperation mit onkogenem H-
Ras überexprimiert. Die Rolle von ILEI in der Tumorentstehung wurde durch subkutane 
Injektionen der ILEI-überexprimierenden Zellen in immun-defizienten Mäuse untersucht. 
Dabei konnte eine ILEI induzierte Aktivierung von β-Catenin und Stat3, die eine wichtige 
Funktion in der EMT einnehmen, detektiert werden, die über die verstärkte Expression 
von Komponenten des PDGF-Signalweges vermittelt werden. Weiters wurde eine 
humane Gewebesammlung auf die Expression und Lokalisation von ILEI untersucht, 
wobei ILEI als Markergen für die Tumorprogression identifiziert werden konnte. Diese 
Ergebnisse zeigten, dass ILEI eine Kooperation mit onkogenem Ras benötigt, um durch 
die Aktivierung von PDGF-R/β-Catenin als auch von PDGF-R/Stat3 eine EMT der 
neoplastischen Hepatozyten zu induzieren. 
In einem weiteren Projekt wurde der Frage nachgegangen, welche Rolle aktiviertes 
Stat3 in Leberkarzinomzellen einnimmt. Dafür wurden verschiedene Mutanten von 
Stat3, welche entweder eine konstitutive Aktivierung dieses Moleküls oder einen Verlust 
der Stat3 Aktivierung zur Folge hatten, in p19ARF defiziente Hepatozyten in Kombination 
mit onkogenem Ras eingebracht. Die Ergebnisse, die bei dieser Untersuchung erzielt 
wurden, zeigten, dass Stat3 in Kombination mit onkogenem Ras und p19ARF Defizienz 
eine suppressive Funktion während der HCC Progression hat. Weiters wurde noch eine 
Expressionsstudie durchgeführt, um jene Gene in Hepatozyten zu analysieren, die durch 
 10
Stat3 an- oder abgeschalten werden. Dabei wurden zwei Gene, nämlich c-Jun und 
MMP-3 identifiziert, die eine wichtige Rolle bei der Induktion einer EMT spielen. 
Zusammengefasst führte diese Untersuchung zur Schlussfolgerung, dass Stat3 in 
Kombination mit onkogenem Ras und TGFβ eine wichtige Rolle bei der hepatozellulären 
Tumorentstehung einnimmt. 
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1. Introduction: 
 
1.1 Hepatocellular carcinoma (HCC) 
Hepatocellular carcinoma (HCC) is one of the most malignant diseases with poor 
survival due to delayed diagnosis which causes more than half of a million deaths per 
year (Parkin, 2001; Song et al., 2004). With regard to the survival rate, HCC is therefore 
the second most lethal cancer of the world (Llovet, 2006). Still today the mechanisms 
underlying this disease are poorly understood and biological markers such as α-
fetoprotein are limited in their sensitivity and specificity. Further commonly used markers 
for HCC are des-γ-carboxy prothrombin and glypican-3 (Pang et al., 2008), ferritin, γ-
glutamyltranspeptidase isoenzmye, alkaline phosphatase, α-1-antitrypsin and aldolase A 
(Lau, 2003). For quantification of the different stages of HCC, several frequently used 
markers are hepatoma-specific gamma-glutamyl transferase isoenzyme, an enzyme that 
is responsible for the degradation of gluthatione and is increased during liver diseases 
and extrahepatic tumors (Yao et al., 2007). Another very important factor for the staging 
of HCC is the transforming growth factor (TGF)-β1, which is increased in more than 50% 
of all HCCs (Deryck, 1998). Due to the increased expression of this cytokine, TGF-β1 is 
therefore used as a marker for mid-stage HCC (Yao et al., 2007). For graduation of 
patients suffering from HCC, different staging forms are available, among them Child-
Pugh`s Classification, Primack-Staging, and Okuda Staging for example (Okuda, 1985; 
Primack et al., 1975; Zhou et al., 2008). Worth mentioning is the tumor-node-metastasis 
(TNM) staging (Huang et al., 2005), emphasizing on different clinicophatological factors 
which are shown to influence the prognosis of HCC (Zhou et al., 2008). Beside all these 
pathological staging, the Edmonson-Steiner grading, a histological way of staging tumor 
patients, is always helpful for more accurate prognosis of patients with HCC (Zhou et al., 
2008). The factors, which influence the stages of the disease and therefore the therapy 
are, according to criteria such as solitary or multiple tumors at stage I, no evidence of 
tumor thrombus in the trunk or portal vein at stage II, no extrahepatic metastasis at 
stage III and metastasis in distant organs or penetration of the visceral peritoneum at 
stage IV (Zhou et al., 2008). Because of these involved factors it is very difficult to treat 
patients with the right therapy. For example, the functionality of the liver is the main 
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cause for liver transplantation or partial hepatectomy (Edmonson, 1954). A lot of 
statistical analysis has to be done to find the right way of staging HCC patients and to 
treat them in the right way to increase the survival rate. 
The incidence of HCC reflects the aetiological factors and the ethnicity of regarding 
countries (Llovet et al., 2003). Infection with Hepatitis B (HBV) or C (HCV) virus, chronic 
alcohol abuse, haematochromatosis, steatohepatitis, and Aflatoxin B1 intoxication are 
among the well-defined major risk factors for liver cirrhosis and subsequent liver 
cancerogenesis (Bosch et al., 1999; Liaw et al., 1986). Gender can also be a factor, 
because males show a 3-fold higher incidence of hepatocellular diseases than females 
(Sherman, 2005; Parkin, 2001). Beside all these mentioned risk factors, the distribution 
of HCC also has an influence on the relevant people. For example, living in Asia or 
Africa can increase the possibility of suffering from a hepatitis B or hepatitis C infection. 
Also the consumption of contaminated food in this area can cause HCC. In western 
countries and Japan, the chance of suffering from hepatitis C is higher than in the rest of 
the world. The excessive consumption of alcohol, a main problem in western countries 
and hematochromatosis also lead to the development of HCC (Bruix, 2003). For a short 
overview about the risk factors causing HCC see Figure 1. 
Still today the ability to detect slow growing tumors in the liver lacks of randomized 
controlled trials. Imaging techniques are very expensive and therefore can neither be 
deployed in African countries nor in Asia. Among these abilities to detect small nodules 
in the liver are precutaneous ultrasonography, multiphasic contrast-enhanced helical 
computed tomography, magnetic resonance imaging and positron emission tomography 
(Song et al., 2004). Once a tumour has been diagnosed, it has to be determined if the 
patient will be treated by surgery or by application of medicaments, including Sorafenib, 
an oral multikinase inhibitor blocking tumor cell proliferation by interfering with the Raf/ 
mitogen-activated protein kinase/ extracellular signal regulated kinase and PDGF-
R/VEGF-R (Zhu, 2007). Other molecular target agents for patients suffering on HCC 
suppress several signalling pathways, as for example Sunitinib and Bevacizumab, which 
block the vascularization of tumor tissue. Others, such as Gefitinib, Eplotinib or Lapatinib 
focus on the inhibition of the epidermal growth factor (EGF) pathway. Monoclonal 
antibodies against several involved signalling pathways were also discovered (Zhu et al., 
2007), either blocking EGF-R of VEGF-R. 
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Many different treatment options are known to combat HCC. Among these therapies are 
liver resection, divided in local hepatectomy and orthotopic liver transplantation, local 
ablative therapy including injections of different cytotoxic agents, hepatic artery 
transcatheter treatments, systemic therapies including chemotherapy or immunotherapy 
and other treatments like gene therapy or supportive therapy (Lau, 2003). The applied 
treatment depends on the liver function of the patient. Good liver function goes along 
with partial hepatectomy. Liver transplantation can be done in patients with early HCC 
and decompensated cirrhosis. For late and severe HCCs, local ablative therapy is most 
commonly used. This includes injections of ethanol percutaneously (PEI) and 
radiofrequency ablation (RFA). All these therapies described so far give the patient a 
survival of 3 years with a rate of 46% to 77%. Another remarkable therapy is the 
transarterial chemoembolisation (TACE), where chemotherapeutics are injected using 
the transhepatic arterty as the route of choice (Lau, 2002). Another way is the systemic 
therapy, where chemotherapeutics are used for HCC interventions. Among these 
chemotherapeutics are cis-platin, interferon-alpha, adriamycin and 5-fluorouracil, which  
showed promising results with a 3-year survival rate of 26% (Leung et al., 1999).  
HCC is proposed to be a long-term result of a chronic liver inflammation effected by one 
of the major risk-factors. The disease itself can be divided in an early, intermediate or 
advanced and end-stage HCC (Llovet, 2003). To classify a patient in one of these 
stages several parameters are of high importance, like tumor size or colonization of 
distant organs. Due to the fact that more than 50% of HCC-patients show an activation 
of TGFβ1, this factor belongs to the group of the most important molecular factors 
involved in hepatocellular tumor progression (Bedossa, 1995; Factor, 1997;Zhao, 1998). 
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Figure 1: Mechanisms of hepatocarcinogenesis (Farazi & DePinho, 2006). 
 
Previous investigations show that genetic and epigenetic alterations result in the 
dysregulation of key oncogenes and already known tumor-suppressor genes, as for 
example p53,  p16 or E-Cadherin (Llovet, 2006). P53, which is frequently  inactivated in 
HBV, HCV, and Aflatoxin B1 induces hepatocellular neoplasia, plays a major role in the 
progression of HCC, because it either contributes to initation or progression of tumor 
growth or both. Another important factor in HCC progression plays the Wnt-pathway 
target gene β-catenin, which translocates to the nucleus and activates several cancer-
related genes like cyclin-D1, which leads to uncontrolled cell growth (Gregorieff & 
Clevers, 2005). Several genomic alterations can lead to the generation of liver-tumors 
including defects in chromosome segregation. Abnormal DNA-damage response 
pathways, as p53 or BRCA2 or genomic alterations, as hypermethylation of CpG-
islands, hypomethylation of several genes result in an increased mutational rate and  
microsatellite instability (Herath et al., 2006). Also a defective DNA-mismatch repair 
belongs to the main modifications involved in the molceular main causes for HCC.  
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1.2 Epithelial-to-mesenchymal transition 
Epithelial-to-mesenchymal transition (EMT) describes the process of cellular conversion 
of epithelial cells to a mesenchymal phenotype by losing the cell-to-cell contacts. This 
process is considered to play a crucial role in carcinogenesis. However EMT also plays 
a major role in embryonic development, especially in somitogenesis and muscle 
formation. Extracellular stimuli are the main source of signals which are necessary for 
cells to undergo such a conversion (Hugo et al., 2007). The upregulation of 
transcriptional repressors of E-Cadherin such as Snail and Zeb1 is involved in the 
transformation of epithalial cells to mesenchymal ones (Eger et al., 2005; Thiery, 2002). 
These newly formed fibroblastoid cells then show features of unlimited cell growth, 
persistent angiogenesis, evasion of apoptosis (Hanahan & Weinberg, 2000) and 
upregulation of typical mesenchymal marker genes.  After this conversion, cells break 
through the basement membrane and invade the blood and lymphoid vessels to reach 
adjacent organs to set up colonies there (Eger and Mikulits, 2005). The main property of 
EMT does not only include the formation of primary tumors, but also gives cells the 
ability to leave solid tumors and build up cancerous colonies in distant organs. For this 
process cells have to undergo the reverse mechanism, also known as mesenchymal to 
epithelial transition (MET) after extravasation. This process and its involvement in tumor 
progression is depicted very clearly in Figure 2. 
A major hallmark in this process plays the activation of several signaling pathways, upon 
them the receptor tyrosine kinases (RTK)s, mitogen-activated protein kinase (MAPK), 
integrin-linked kinase (Lackmann et al., 1998), phosphatidyl-inositol 3 kinase (PI3K) as 
well as the activation of small GTPases, as for example Rac and Rho (Schmitz et al., 
2000), platelet derived growth factors (PDGF) and receptors, and transforming growth 
factor (TGF) β signalling (Eger et al., 2005; Heldin, 2004).  
Among the major attributes of EMT, the loss of tight and adherens junctions and the loss 
of its major constituent such as E-Cadherin and ZO-1 respectively, is crucial. Along with 
this observation is the upregulation of the repressors of the marker genes as for 
example Snail, Twist, deltaEF1 or Slug. Also the accumulation of β-catenin in the 
nucleus after the release from the adherens-junction complex, consisting of E-cadherin, 
β-catenin and p120CTN, plays an important role in the EMT process (Zhai et al., 2008). 
Rearrangement of the cytoskeleton from cortical actin to actin stress fibres is an 
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indicator of migratory cells (Zavadil & Bottinger, 2005) and therefore a hallmark of 
ongoing EMT. Among the activated signaling pathways, the Ras/MAPK pathway plays a 
critical role in the establishment of mesenchymal cells.  
 
 
 
Figure 2: Sites of EMT and MET in the progression of cancer (Thiery et al., 2002). 
 
Several in vitro and in vivo models help to gain more information about the cellular 
processes involved in EMT.  These models have been investigated the molecular events 
resulting in the identification of various important molecules for the ongoing EMT 
process. To study the process of EMT in different cancers, several cell lines were 
established overexpressing oncogenic Ras. These cells were then treated with TGFβ to 
undergo an EMT and can be used for further analysis. Not only in vitro models were 
generated, but also in vivo models were established employing knock-out experiments 
or transplantation studies or models for intravital imaging of all invasion (Eger et al., 
2005). Under the most important mechanisms is the upregulation of transcriptional 
repressors for the expression of E-Cadherin, among them Twist, which plays a major 
role in metastasis formation (Karreth & Tuveson, 2004).  
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1.3 EMT and HCC progression 
In recent studies several genes  such as Laminin-5 or Stat5b were identified to cause 
EMT, alone or in combination with TGFβ1, in human HCC (Giannelli, 2005; Lee, 2006). 
As a new factor involved in human EMT, Laminin-5  was found during the formation of 
metastasis. Giannelli et al. found out that Laminin-5 was only expressed in tumor tissue 
compared to peritumoral sections. Also the E-cadherin repressors Slug, Snail and β-
catenin showed an increased expression in HCC samples revealing a role for this factor 
in EMT. While E-cadherin expression was decreased in the samples, β-catenin 
accumulation in the nucleus was increased indicating an important role of these two 
factors during EMT. All investigated human invasive cells did not change their 
morphology when treated with TGFβ1, a main factor responsible for EMT induction in 
the liver, but showed a dramatic morphological change after treatment with Laminin-5 
leading to scattered cells and long  shaped cell bodies. Non-invasive cell lines induced 
with both TGFβ1 and Laminin-5 showed a phenotypical transition together with 
upregulation of Snail and downregulation of E-Cadherin. Furthermore, it has been 
shown that TGFβ1 can induce EMT with the help of Laminin-5 due to the induction of 
integrin α3 β1 subunit which are the main receptors for Laminin-5. 
Lee et al. found a second factor playing a role in HCC, especially in EMT. In particular, 
an induction of the isoform Stat5b and not Stat5a was shown to be activated in human 
HCC samples. Furthermore this process is influenced by HBV infection. During this 
infectious disease, HBX is transactivated and can induce the increased expression of 
Stat5b. An upregulation of this transcription factor leads to an increased invasion ability 
of investigated metastatic HCC cell lines. In these cell lines the expression of Stat5b 
upregulates E-cadherin repressors and therefore causes an EMT activation. This was 
the first hint for Stat5b and its correlation with the aggressive behaviour of cells causing 
HCC and the induction of EMT under activated HBX gene. Alltogether these findings of 
Gianelli and Lee may help to generate new therpaeutic targets for the treatment of HCC 
(Lee, 2006). 
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1.4 The role of TGFβ in hepatocellular cancer progression 
The multifunctional cytokine TGFβ is responsible for the control of proliferation, 
differentiation and many other functions in a wide range of different cell types (Sporn et 
al., 1986; Dewilde et al., 2008). Studies on the function of TGFβ revealed a role in tumor 
suppression and tumor progression. At least three different TGFβ-ligands and two 
different receptors are known with a very high similarity (Abou-Shady et al., 1999). As a 
co-receptor and therefore necessary for the activation of this pathway, β-glycan was 
found (Feng, 2005; Shi, 2003). From these three ligands, the peptide TGFβ1 plays the 
most prominent role in tumor cells (Akhurst & Derynck, 2001). The role of this peptide in 
cancer influences the premalignant state, the loss of tumor suppression, the migratory 
potential of the cells and the modifications of the microenvironment after metastatic 
colonization (Massague, 2008). 
The loss of the tumor suppressive function of TGFβ is frequently caused by disruptions 
of the receptors, which consist of characteristically short nucleotide repeats in their 
kinase region (Grady et al., 1998; Pardali & Moustakas, 2007; Massague, 2008). Also 
mutations of the target genes, the Smads, can occur and lead to an inhibition of the 
physiologic role of the TGFβ pathway. As recent findings, epigentic alterations of several 
components of the pathway have been reported (Chen & Chang, 1997; Munoz-Antonia 
et al., 1996) which can lead to inhibition of the inhibitory effect of TGFβ on cell 
proliferation. 
In the liver, the function of this growth factor can be classified in a cytostatic and an 
apoptotic one, depending on the physiological conditions of the surrounding liver tissue 
(Rossmanith & Schulte-Hermann, 2001). For activation of the TGFβ-signaling pathway 
TGFβ has to bind to its co-receptor, β-glycan. This binding induces a heterogenic 
complex formation of TGFβRII and TGFβRI. This process leads to the phosphorylation 
of the regulatory domain of TGFβRI by the kinase domain of TGFβRII and is therefore 
activated. After the activation of TGFβRI intracellular proteins, the so-called receptor 
activated Smads (R-SMADs), a subclass of Smad proteins, among them Smad2 and 
Smad3, are phosphorylated on their C-terminal serine residues. In normal cytoplasm 
Smad2 and Smad3 can bind to several proteins, including also the Smad anchor for 
receptor activation (SARA) and due to this binding, the R-Smads stay inactive in the 
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cytoplasm (Siegel et al., 2003). After the release of Smad2 and Smad3 from SARA, this 
complex forms a trimeric protein complex together with the Co-Smad Smad4 and is then 
shuttled in the nucleus of regarding cells (Pardali & Moustakas, 2007) where it activates 
several target genes. An overview of the TGFβ-pathway is shown by Figure 3.  
Due to the fact that in more than 50% of all human HCCs TGFβ1 is upregulated and 
influences the surrounding tissue by uncontrolled proliferation, more about the role of 
this factor has to be known. In last years, different mouse models have been generated 
to investigate the pro-tumorigenic activity in different tissues. In the skin, TGFβ1 
suppresses the growth of tumors, but accelerates the rate of metastasis (Cui et al., 
1996). For breast cancer models the direct induction of TGFβ1 did not affect primary 
breast tumor formation, but it increased the amount of lung metastasis. These results 
confirmed an autocrine action of TGFβ in promoting metastasis (Muraoka-Cook et al., 
2004). For analyzing the overexpression of TGFβ ligands and their receptors further 
investigations were done emphasizing on the production and secretion of TGFβ. Again 
breast cancer cell lines expressing oncogenic H-Ras showed an indcution of EMT and a 
higher migratory behaviour followed by a higher metastasis rate (Oft et al., 1996). The 
ability of TGFβ to induce the transition of epithelial cells to gain a mesenchymal 
phenotype is crucial for the formation of hepatic neoplasia (Moustakas et al., 2007). 
To explain the tumor promoting or pro-metastatic role of this polypeptide it is worth 
mentioning that cancer cells often overexpress TGFβ (Derynck, 1986). Due to this 
overexpression a phenotypical change of epithelial cells occurs, a process called EMT, 
which goes along with the upregulation of the expression of matrix-metalloproteinases 
(MMPs), which leads to a higher migratory potential of these cells. Recent obseravtions 
claimed an induced neovascularization of tumorigenic colonies (Hasegawa et al., 2001; 
Ito et al., 1995) along with the formation of metastasis. A novel factor, found in breast 
cancer cell lines, playing a role in the formation of lung metastasis after TGFβ induction 
is angiopoietin-like protein-4 (Angptl4). Tumor cell-derived Angptl4 starts to disrupt the 
vascular endothelial cell-cell junctions, increases the blood pressure to passage more 
blood through the capillaries and facilitates the trans-endothelial passage of tumor cells 
(Padua, 2008).  
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Recent studies on therapeutic strategies against TGFβ focus mainly on the manipulation 
of the TGFβ-pathway (Yingling et al., 2004). Among these therapeutic approaches, low 
molecular weight inhibitors, enzymes modifiying the small GTPases of the Ras family, 
neutralizing antibodies and antisense RNA-approaches against TGF-β signalling 
components have been established (Arteaga et al., 1993; Schlingensiepen et al., 2005; 
Witham et al., 2003). Despite all this knowledge about TGF-β signaling, major research 
has to be focused on the TGFβ-induced EMT in tumor progression.  
 
 
1.5 The role of Platelet-derived growth factor signaling in cancerogenesis: 
Platelet-derived growth factors (PDGF) are described as mitogenes of myofibroblats and 
are involved in the conversion of epithelial cells to spindle-shape like mesenchymal cells  
(Heldin & Westermark, 1999). This highly conserved molecule family consists of five 
isoforms PDGF-A, -B, -C, –D and –E and two receceptors PDGFR-α and PDGFR-β, 
Figure 3: The TGFβ signaling pathway (Shi & Massague, 2003). 
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which can form homodimers and heterodimers. They also have a very high similarity to 
vascular-endothelial cell growth factors (VEGF) and therefore play a role in blood vessel 
formation (Joukov et al., 1997). Beside these 5 PDGF-ligands, two different receptor 
tyrosine kinases, referred to as PDGF-Rα and PDGF-Rβ, which are members of the 
cystein knot family of proteins and complete this signaling pathway. Both receptors 
consist of five immunoglobulin-like domains and intracellularily there is a common 
tyrosin kinase domain with an characteristically inserted sequence without kinase-
homology (Claesson-Welsh et al., 1988; Matsui et al., 1989; Yarden et al., 1986). The 
binding affinity of the ligands to their receptors is shown in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Mammalian PDGF/PDGFR binding interactions (Soriano et al., 2003). 
 
Upon receptor dimerization these two receptor isoforms can form homo- or heterodimers 
(Hammacher et al., 1989; Kanakaraj et al., 1991; Seifert et al., 1989). For activation of 
these receptor tyrosine kinases, autophosphorylation of tyrosine residues in trans at the 
receptor is necessary (Heldin & Ostman, 1996). After this process, phosphorylation of 
tyrosine residues in the activation loop induces the kinase domain and then the activated 
receptor provides SH2-docking sites for several signalling molecules. Among the SH2-
binding molecules are members of the Src family, PI3K, phospholipase γ, the tyrosine 
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phophatase SHP-2, Grb2/Sos, STAT and the GTPase activating protein (GAP) for Ras 
(Heldin et al., 1998).  Together with the classical MAPK pathway, PDGF signalling is 
claimed to play a role in tumor progression and metastasis formation (MacDonald et al., 
2001). The activation of the PI3K- together with the PDGF-pathway is assigend to 
influence apopotosis protection and a higher migratory potential including the stimulation 
of small GTP binding proteins of the Rho-family (Barres et al., 1992; Hawkins et al., 
1995; Hooshmand-Rad et al., 1997; Yao & Cooper, 1995). 
In recent investigations the physiological functions of PDGF are assumed to play a role 
in embryonic development, supported by the findings in PDGF-knock-out mice, which 
are dying during embryogenesis. Functions of this pathway are also the formation of the 
vascular system due to its relation to VEGF and tissue homeostasis, where it regulates 
the interstitial fluid pressure and stimulation of wound (Heldin & Westermark, 1999). On 
the other hand PDGF is described to induce diseases due to its dysregulation in many 
different tissues.  Among these effects are developmental defects, inflammation, 
artheriosclerosis, fibrosis and cancer. Latest experiments showed a function of PDGF in 
HCC. Overexpression of PDGF-C is assumed to cause liver fibrosis, steatosis and HCC 
(Campbell et al., 2005). In recent findings it is shown that TGFβ1 causes PDGF 
activation and an autocrine PDGF secretion in cells expressing H-Ras (Gotzmann et al., 
2006). Together with these findings, the accumulation of β-Catenin in the nuclei of 
tumorigenic cells was observed (Fischer et al., 2007). Similar results in breast-cancer 
cell lines revealed an important role of TGFβ1 and PDGF in formation of neoplastic 
tumors (Jechlinger, 2006).  
But still today the understanding of PDGF in tumour progression and metastasis 
formation and the cooperation  with TGFβ signaling are not completely understood and 
therefore further investigations have to be done. 
 
 
1.6 Wnt signaling and its role in cancer 
The Wnt signaling is highly conserved having its role in embryonic development and 
cancer. This signaling pathway functions as a morphogen which is secreted beyond cell 
boundaries and influences the transcription of several factors in adjacent cells regulating 
processes such as proliferation, survival or differentiation. One of the major factors in 
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this pathway is β-catenin which can interact with E-cadherin at the cell-boundaries and 
can translocate into the nucleus and bind to the lymphoid enhancer factor (LEF) 1, which 
was discovered first in the early 90ties (Behrens et al., 1996; Huber et al., 1996). Further 
regulators of the Wnt-pathway were found by genetic analysis in Xenopus embryos and 
Drosophila (Behrens et al., 1998; Itoh et al., 1998; Zeng et al., 1997). 
At the moment 19 Wnt genes in the human genome are known all playing a role in cell 
polarity, embryonic induction, cell fate determination and tissue hoemostatsis (Lee, 
2006). There are three different  major Wnt signalling pathways among them the 
canonical pathway (see Figure 5), which is characterized by the activation of Wnt target 
genes by β-catenin (Logan & Nusse, 2004). The second major pathway involves Rho A 
and Jun Kinase (Veeman et al., 2003). The third cascade contributing to the Wnt 
signalling pathways is calcium dependent and therefore activates the protein kinase C 
and calmodulin-dependent protein kinase II (Kuhl, 2000; Lustig & Behrens, 2003; 
Sheldahl, 1999; Slusarski, 1997). The classical canonical Wnt pathway starts with the 
binding of one of the 19 Wnt ligands to their cognate Frizzled (Fzd) receptors at the cell 
surface, from which 10 different are known so far. After binding of the ligand to its cognat 
receptor, proteins belonging to the dishevelled protein family are activated and therefore 
change the amount of β-catenin that can translocate to the nucleus (Birchmeier et al., 
2008). These signalling steps thereafter lead to the release of β-catenin from the 
boundary complex consisting of α-catenin and E-cadherin and causes the translocation 
into the nucleus occurs. There β-catenin activates its partners Tcf/LEF1 and induces the 
transcription of Tcf/LEF1 bound target genes. In the absence of Wnt-ligands, β-Catenin 
gets phosphorylated by GSK3β and ubiquitinilated and afterwards degraded. Very low 
levels of β-Catenin in the cytoplasm lead to repression of Wnt target genes (Klaus & 
Birchmeier, 2008). Several inhibitors of this pathway are already known playing a role in 
different signalling steps. Dickkopf is a competitive antogonist for binding of Wnt/Fzd to 
LRP receptors (Roman-Gomez et al., 2004). In the absence of Wnt, TCF is able to 
repress target genes in the nucleus (Bienz, 1998; Brannon et al., 1997; Riese et al., 
1997) by forming a complex together with the Wnt inhibitor Groucho, which causes the 
recruitment of histon deacetylases (Cavallo et al., 1998; Chen & Struhl, 1999) 
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Figure 5: The canonical Wnt-pathway (Eisenmann et al., 2005). 
 
The role of this pathway in cancerogenesis is still poorly understood, but recent studies 
revealed several disorders caused by members of the Wnt pathway. Circumventing the 
inhibitory effect of Wnt signaling by downregulation of its repressor Dickkopf (Dkk) 
through hypermethylation or loss-of-function mutations were found in different tumors 
and play a role also in many other diseases (Caldwell et al., 2004; Terasaki et al., 2002; 
Vider et al., 1996), as for example in cancer, especially in HCC, non-small lung cancer 
and colon carcinoma (Fuerher, 2008). Wnt β-catenin signalling also plays a role in the 
cardiovascular system and the dysregulation of this pathway may lead to cardiovascular 
diseases as well as neurodegenerative diseases as for example Schizophrenia or 
Alzheimer`s disease (Klaus & Birchmeier, 2008).  
In HCC patients the activated Wnt β-catenin pathway can be found in more than 50%. In 
these patients the accumulation of β-catenin in the nucleus results in a poor prognosis. 
On the other hand there are repots showing that the expression of β-catenin in the 
cytoplasm might result in a better curing (Austinat et al., 2008). Recent results identified 
a role of Wnt signalling in regeneration and ageing and therefore gave rise to the idea 
that this pathway may play a role in cancer stem cells. Several studies on this topic 
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showed an increase of nuclear accumulated β-catenin in regions responsible for the 
tumor progression not only in the liver but also in the colon (Jung et al., 2006). There 
accumulation of β-catenin causes an induction of EMT due to downregulation of E-
cadherin and degradation of the adherens and tight junctions by matrix-
metalloproteinase 14 (Brabletz et al., 2006) and therefore indicating an important role of 
β-catenin in tumor progression.  
 
 
1.7 Signal transducers and activators of transcription 
Another important pathway linked to tumor pogression is the Signal transducer and 
activators of transcription (Stat) pathway, Stat3. This protein family consists of 7 Stat 
proteins which are highly similar in their protein structure (Darnell et al., 1994; Horvath, 
2000; Lackmann et al., 1998; O'Shea, 1997). Each Stat protein shows a transactivation 
domain at the C-Terminus, followed by a SH2-domain and a DNA-binding domain in the 
center of the protein (Becker et al., 1998; Chen et al., 1998). Many  receptors at the cell 
membrane such as cytokine receptors and receptor tyrosine kinases are able to activate 
these Stat proteins in the cytoplasm (Levy & Darnell, 2002).  
Activation of Stat proteins occur after the binding of cytokines or growth factors to their 
cognate receptors. Receptor dimerization takes place followed by autophosphorylation 
of the Janus kinase (Roberts et al.), which is non-covalently bound to specific receptors 
(Levy & Darnell, 2002). As a next step the Janus kinases (Jak), which is now activated, 
phosphorylates the receptor and therefore provides binding sites for the SH2-domain of 
Stat molecules. These bound Stat proteins are then phosphorylated by the Jaks and 
translocate into the nucleus where they can activate several target genes (See Figure 
6).  
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Figure 6: The canonical JAK-STAT pathway (Levy & Darnell, 2002). 
 
Several inhibitors of Stat activation can be found within a cell, among them SH2-
containing phosphatases (SHP), proteins which dephosphorylate the receptor or 
suppressors of cytokine signalling (SOCS), which can block the entire signaling 
mechanism (Krebs & Hilton, 2001). Epigenetic inactivation of SOCS-3 apart from SOCS-
1 may be involved in tumor progression and metastasis of HCC caused by HCV 
infection (Ogata et al., 2006). Downregulation of SOCS-3 is accompanied with 
constitutive expression of Stat3 and therefore leads to the upregulation of numerous 
tumor-promoting genes (Yoshikawa, 2001; Yoshimura, 2006).  
The role of Stat proteins in cancer is still poorly understood but recent studies showed a 
function of Stat1, Stat3 and Stat5 in cancerogenesis. It has been shown that Stat1 has 
its role in the antiviral defense, inflammation and injury in the liver and is mainly 
activated by IFN-α/β and INF-γ. Stat3 itself acts in the acute phase esponse, 
hepatoprotection, liver regenration, glucose homeostasis and hepatic lipid metabolism 
and is mainly activated by interleukin (IL)-6 and its related cytokines as well as IL-22. 
For the function of Stat5 in the liver, only few results are known among them the 
expression of a variety of hepatic genes such as cytochrome P-450, gluthatione S-
transferase, sulfotransefrase enzyme, growth hormone receptor, serine protease 
inhibitor Sp12.1, insulin growth factor I and hepaptocyte growth factor. These genes are 
involved in the metabolsim, growth and differentiation in the liver. Stat5 is activated by a 
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wide variety of cytokines in the immune and hematopoietic system (Gao, 2005). Stat3 
exists in two isoforms, Stat3α and Stat3β which might have different fuctions. Stat3β on 
its own is able to induce and repress genes depending on different cellular environment 
(Dewilde et al., 2008). Further differences between these two alternatively spliced 
isoforms is the lack of 55 amino acid residues at the C-terminus which are replaced by 7 
amino acids specifically for Stat3β. At the level of expression, Stat3β shows a decreased 
expression but is able to be activated especially in hepatocytes at the same level as 
Stat3α after inflammation (Biethahn et al., 1999; Hevehan et al., 2002). The function of 
the specific 7 amino acid tail is still poorly understood but may play a role in the DNA 
binding acticity (Yoo et al., 2002). Many tumors show an overexpression of activated 
Stat3 due to increased levels of IL-6. Introduction of dominant negative forms of Stat3 in 
mice enhanced the apoptotic potential of breat cancer cells showing the necessity of this 
protein for growth regulation (Garcia et al., 2001).  
Among the oncogenic functions of Stat3 are its anti-apoptostic, mitogenesic, pro-survival 
and pro-proliferative, which can finally lead to malignant transformation. Also the 
dysregulation of the immune system has to be mentioned by inhibiting Th1 
immunstimulatory molecules (Kortylewski et al., 2008). 
In recent studies of HCC it was shown that the activation of the Ras- and Jak/Stat 
pathway was enhanced in all HCCs which goes along with the suppression of at least 1 
Ras inhibitor and 2 Jak/Stat inhibitors, namely the SH2-containing phosphatases (SHP) 
and the suppressors of cytokine signalling (SOCS). All these inhibitory factors cause a 
suppression of cytokines responsible for Stat3 activation (Calvisi et al., 2006). 
 
 
1.8 The role of E-Cadherin in EMT 
The adherenes-junction protein E-cadherin belongs to the cadherin superfamily of  
calcium dependent adhesion glycoproteins. The gene itself has 16 exons spanning 100 
kD of genomic DNA. The structure is similar to that of cadherins and shows specific five 
extracellular cadherin repeats followed by a transmembrane region and a highly 
conserved intracellular tail domain. Knock-out experiments revealed a function of this 
gene in migration and tumor progression as well as invasion and metastasis (Larue et 
al., 1994). Therefore loss of E-Cadherin resulted in a transition of adenoma cells to 
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carcinoma cells and is the cause of the tumor progression and not a consequence 
(Chirstofori et al., 2003). 
The crosstalk of epithelial cells and cells of the surrounding tissue has great influence on 
the progression of neoplasia in the hepatocellular system. One of the most prominent 
factors playing a role in this process is the adherens junction protein E-cadherin (Giehl & 
Menke, 2008). Recent findings raise the question if epithelial cells dysregulate their 
shape or change their microenvironment to form tumors (Comoglio & Trusolino, 2005). 
In the liver, inflammation occurs and therefore is a trigger for the change of the 
microenvironment of the cells. Responsible for this process are cytokines and 
chemokines, which are secreted by several activated fibroblast and stellate cells 
(Bachem et al., 1998; Kleeff et al., 2007). In more than 50% of human HCCs TGFβ1 and 
members of the PDGF-family, which are secreted by immune cells are responsible for 
the progression of tumors in the inflammed liver (Esposito et al., 2004). Due to this 
process cells undergo EMT and are able to migrate to distant organs and to form 
colonies there. During EMT, one of the most important changes is the loss of the 
adherens junction protein E-cadherin (Gumbiner, 1996; Kemler, 1993). The loss of E-
Cadherin is often transcriptionally silenced in human tissues caused by epigenetic 
changes of the promoter (Gilles et al., 1997; Rodrigo et al., 1999) either by 
hypermethylation or by acetylation.  
 
 
 29
 
Figure 8: The E-cadherin complex (Yamada et al., 2005). 
 
Due to decreased p120ctn content, E-cadherin is degraded (Ireton et al., 2002) and the 
cells therefore lose their tight adherens junction (for regular E-cadherin complex see 
Figure 8) and gain a more fibroblastoid phenotype. As a first factor involved in the 
downregulation of the adherens function of E-cadherin, Snail was found. Snail was also 
shown to cause EMT (Peinado et al., 2007; Batlle et al., 2000; Cano et al., 2000). 
Besides Snail, Slug, Zeb1, Zeb2 and Twist were shown to downregulate the 
transcription of E-cadherin and therefore lead to the phenotypical change important for 
EMT (Comijn et al., 2001; Eger et al., 2005). Also other repression mechanisms exist 
which alter the expression level of E-cadherin. For example, histon deactelyses are 
involved in the repression (Hemavaty et al., 2000), or even post-transcriptional 
regulation mechanisms play a prominent role in the regulation of EMT by downregulating 
the adherens junction protein.  
TGFβ1 plays a major role in the decreased expression of E-cadherin. Recent studies 
showed a collaboration of TGFβ1 and β-catenin in the induction of EMT (Peinado et al., 
2004). After increased expression of the profibrotic factor TGFβ1, phosphorylation of β-
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catenin takes place and the junctional complex is destabilized and dissolved (Janda et 
al., 2006).  
 
 
1.9 The p19ARF null hepaoctye cell model 
To analyse molecular mechanisms in the liver,  p19ARF null hepatocytes were 
established to provide a cell model for in vitro studies. Due to mitogenic inactivity of 
hepatocytes, genetic alterations such as lack of p19ARF were introduced. Of great 
interest was the ability to generate immortalized cells which are capable to repopoulate 
a damaged liver and therefore show some important aspects of primary hepatocytes. 
Knock-out studies on the p19ARF/MDM2/p53 pathway (see Figure 9), which plays a 
major role in the limited life-span of primary hepatocytes, revealed a unique opportunity 
to circumvent cell cycle arrest and senescence of hepatocytes (Lowe & Sherr, 2003; 
Mikula et al., 2004; Randle et al., 2001).  
 
 
Figure 9: The Ink4A/Arf locus (Randle et al., 2001). 
 
These immortalized cells derived from p19 null mice show similar properties as wild type 
hepatocytes, including genetic stability. These cells, which were called MIM1-4, were not 
able to form tumors after subcutaneous injection. All immortalized cells still expressed 
the liver specific markers such as albumin, alfa fetoprotein, HNFα and HNF4α and were 
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sensitive to Fas-induced apoptosis (Mikula et al., 2004). Tumor formation was only 
established after transformation of  these hepatocytes with oncogenic H-Ras.These H-
Ras transformed cells were used to establish a hepatocellular tumor model in vitro for 
further analysis of the role of ILEI in the liver tumorigenesis.  
 
 
1.10 Interleukin-like EMT Inducer (ILEI) and its role in EMT induction and cancer 
progression 
Expression profiling of mammary epithelial tumor cells involved in EMT and metastasis 
revealed a cluster of 30 specific genes involved in EMT (depicted in Figure 10). Upon 
this, a novel gene was identified, called interleukin-like EMT inducer (ILEI), which is 
necessary and sufficient to cause EMT, tumorigenesis and metastasis of normal 
epithelial cells (Mackenzie, 2006; Waerner et al., 2006).  
ILEI on its own showed no sequence homology to already known genes (Zhu et al., 
2002) and as a related protein to interleukins it shows the four helix-loop-helix bundles 
which are important for this family. Due to this, it belongs to a family of secretory 
proteins, among them cytokines, chemokines and other important regulators (Balkwill, 
2004). Studies on ILEI found an elevation of translated and secreted ILEI in murine 
mammary epithelial cells that co-express oncogenic H-Ras and undergo EMT after 
treatment with TGFβ (Mackenzie, 2006). For studying the involved signaling pathways 
associated with ILEI-induced EMT, the authors focused on the Ras-pathway and TGFβ 
induced EMT (Janda et al., 2002). For this purpose cell lines overexpressing ILEI were 
generated, which showed an induced EMT-phenotype and reverted after treatment with 
siRNA against ILEI (Mackenzie, 2006). Inhibitor studies on the Erk/MAPK pathway 
revealed a necessary activation of the Ras-signaling pathway for ILEI-dependent EMT 
induction. In further experiments the biological function of ILEI was found to be of great 
impact for the formation of tumors and metastasis. This was studied by subcutanous 
injections of overexpressing ILEI-cells in nude mice. These tumors showed the 
characteristic downregulation of E-cadherin and upregulation of Vimentin indicating an 
EMT (Mackenzie, 2006; Waerner et al., 2006). The formation of secondary tumors in the 
lung of these mice after injection of ILEI-overexpressing cells demonstrated the 
involvement of ILEI in metastasis formation (Waerner et al., 2006). 
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Waerner et al. could further show a realtionship between ILEI and the formation of 
carcinomas in humans. Human colon carcinomas showed an increased expression 
pattern of cytoplasmic ILEI, which was prominent at the invasive front (Mackenzie, 
2006). It was found that strong cytoplasmic ILEI expression in breast tumors correlated 
with increased metastasis and poor prognosis (Mackenzie, 2006; Waerner et al., 2006). 
Therefore ILEI could represent a novel diagnostic marker for the progression of 
carcinomas (Waerner et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Identification of ILEI (picture kindly provided by T. Waerner). 
 
 
1.11 Relevance of the study 
The major goal of the PhD thesis was to address the question whether ILEI is a crucial 
regulatory protein in hepatocellular EMT and HCC progression. Therefore the aim was 
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to characterise the role of ILEI in epithelial plasticity of hepatocytes and its role in cancer 
progression and metastasis. Further aims included the analysis of other key signalling 
pathways such as Erk/MAPK, Stat3 and Wnt/β-catenin. To bridge mouse and human 
hepatocarcinogenesis, a human tissue array was used to analyse ILEI expression and 
cellular localization. These studies revealed that ILEI is crucially involved in the EMT of 
malignant hepatocytes in cooperation with H-Ras through the activation of PDGF-R/β-
catenin and PDGF-R/Stat3.  
Due to the fact that Stat3 was activated in hepatocytes after treatment with TGFβ, a 
possible role of Stat3 in hepatocellular tumor progression was further investigated. This 
analysis revealed an upregulation of c-jun and MMP-3 in Stat3-overexpressing 
hepatocytes. Furthermore, studies on the tumorigenesis of Stat3 expressing 
hepatocytes in SCID mice led to the finding that Stat3 shows a tumor suppressive role 
rather than a tumor promoting one, which might depend on the deficiency of the p19ARF 
protein. Therefore, the crosstalk between Stat3 and p19ARF could play an important role 
in the EMT and hepatocellular carcinoma progression. 
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Abstract 
Hepatocellular carcinoma (HCC) correlates with poor survival of patients due to delayed 
diagnosis and frequent recurrence after adjuvant treatment. The majority of malignant 
hepatic lesions shows a tremendous heterogeneity in differentiation patterns and 
molecular signatures which challenges efficient therapeutic intervention. Here we 
discuss aspects on which route hepatocytes progress towards epithelial lineage 
commitment during liver repopulation and further resume configurations of hepatocyte 
differentiation during liver tumorigenesis. We particularly focus on the epithelial to 
mesenchymal transition (EMT) of hepatocytes and its consequences upon the 
progression of HCC which depends on the synergy of transforming growth factor (TGF)-
β signaling and the hyperactivation of Ras-subeffectors. Recent insights into the 
epithelial plasticity of malignant hepatocytes revealed that activation of platelet-derived 
growth factor (PDGF) links TGF-β signaling to nuclear β-catenin accumulation upon 
EMT. PDGF-dependent activation of β-catenin reduces cellular turnover and provides 
protection of malignant hepatocytes against anoikis, the latter known as a prerequisite 
for dissemination of carcinoma and a feature of metastatic cancer stem cells. Finally, we 
discuss the cancer cell fate determination by integrating the repertoire of hepatocellular 
differentiation in a novel concept of liver carcinoma progression. 
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Stem cell activity in the adult liver 
The liver belongs to a typical low turnover tissue which shows an enormous regenerative 
potential in response to resection or acute chemical injury (Michalopoulos and 
DeFrances, 1997). The hepatocyte represents the most abundant and versatile cell type 
of the liver, and is the cellular origin of HCC. Although hepatocytes are highly 
differentiated and quiescent under healthy conditions, they possess an astonishing 
proliferative capacity and are the major source for hepatocyte replacement upon liver 
repopulation (Fausto, 2004). Besides the regenerative potential of hepatocytes, oval 
cells provide a liver stem cell repository with the ability to differentiate into both 
hepatocytes and bile duct epithelial cells (cholangiocytes), thus representing bipotent 
progenitor cells (Roskams, 2006; Shafritz and Dabeva, 2002; Thorgeirsson and 
Grisham, 2003). In addition, bone marrow-derived hematopoietic stem cells have been 
proven to undergo metaplasia into cells with hepatic epithelial cell lineage capability 
(Lagasse et al., 2000; Petersen et al., 1999) which is caused to a certain extent by the 
fusion with hepatocytes (Vassilopoulos et al., 2003; Wang et al., 2003). For all different 
liver stem cell compartments involved in tissue homeostasis and organ repair, 
corresponding ex vivo cultures have been essential for the study of underlying molecular 
mechanisms and the subsequent treatment of liver diseases (Forbes et al., 2002; Sell, 
2001).  
 
Immortalized hepatocytes yield liver progenitor cells capable to restore the 
damaged liver 
The access to hepatocytes with liver reconstituting activity is hindered by multiple 
obstacles, among them the very limited potential to expand hepatocytes in culture. 
Innate surveillance mechanisms linked to tumor suppressor activities are responsible for 
blocking cell cycle and for rapidly evoking senescence of hepatocytes ex vivo (Sell, 
2001). Inactivation of the p19ARF/MDM2/p53 pathway therefore offers an unique 
opportunity to obtain limitless lifespan by the ablation of both cell cycle arrest and 
senescence (Lowe and Sherr, 2003; Sherr, 2001). On the one hand, loss of p19ARF 
(p14ARF in human) decreases the growth-suppressive functions of p53, while maintaining 
the Arf-independent activities of this protein. On the other hand, disruption of p19ARF 
function is sufficient to circumvent senescence without losing genetic stability. 
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 In a recent study, we showed that immortalized hepatocytes from p19ARF null mice 
display a high degree of epithelial organization as detected by the expression of the 
polarity marker ZO-1, and the adherens junctions and desmosomal marker proteins 
such as E-cadherin, β-catenin, p120-catenin and desmoplakin at cell-to-cell contacts 
(Gotzmann et al., 2006; Mikula et al., 2004). Importantly, these p19ARF null hepatocytes, 
referred to as MIM cells, exhibit functional differentiation by expressing hepatic markers 
such as e.g. albumin, α-fetoprotein (AFP), hepatocyte nuclear factor (HNF)-1α, HNF-4α, 
phenylalanine hydroxylase, ApoAI and ApoAII. Typical for hepatocytes, MIM cells are 
sensitive to Fas-mediated apoptosis induced by the Fas antibody Jo-2, and exogenous 
expression of either anti-apoptotic Bcl-2 or Bcl-XL efficiently reduces cell death events 
(Mikula et al., 2004). 
 To affirm that MIM cells represent functional hepatocytes, MIM cells expressing 
green fluorescent protein (GFP) were orthotopically transplanted into SCID mice after 
Fas-dependent apoptotic liver damage. MIM-GFP donor hepatocytes contribute to liver 
restoration, thus being able to reconstitute the liver in vivo (Mikula et al., 2004). 
Transplanted MIM-GFP cells are organized in ductular structures comparable to canals 
of Hering, whereas a lower portion of these hepatocytes localizes in small-sized clusters 
as well as in isolated cells scattered throughout the entire liver. The emergence of such 
small-sized clusters of transplanted MIM-GFP hepatocytes might be an effect caused by 
the Jo-2 mediated destruction of the liver architecture. Intriguingly, donor cells organized 
in canals display a hepatocyte-like morphology with a high cytoplasm to nucleus ratio as 
well as a cholangiocyte-like phenotype with poor cytoplasmic portions (Shafritz and 
Dabeva, 2002). 
 Transplantation of apoptosis-protected MIM-GFP-Bcl-XL hepatocytes and 
successive Fas-mediated injury enhances donor-derived liver restoration, providing 
strong evidence that p19ARF null hepatocytes are able to generate liver progenitor cells. 
As observed with MIM-GFP hepatocytes, most of MIM-GFP-Bcl-XL donors localize in 
ductular structures, suggesting the potential of MIM hepatocytes to generate progenitor 
cells after successive liver regeneration. To determine whether MIM-Bcl-XL donors 
represent hepatic precursor cells, markers characteristic for the various liver cell types 
were used for co-localization with the transplantation marker GFP (Vessey and De La 
Hall, 2001). (i) AFP and albumin for oval cells and fetal hepatocytes, (ii) M2-pyruvate 
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kinase (M2-PK) for oval cells, fetal hepatocytes and cholangiocytes, and (iii) cytokeratin 
(CK) 19 for cholangiocytes. This analysis showed that engrafted MIM-GFP-Bcl-XL donor 
cells stain positive for AFP, M2-PK, albumin and CK19, which led to the conclusion that 
immortalized hepatocytes are capable to form bile ducts and to express markers specific 
for both oval cells and embryonic hepatocytes after transplantation in vivo (Mikula et al., 
2004). 
 In the context of the liver in vivo, the majority of MIM hepatocytes reside in ductular 
structures comparable with canals of Hering, and display characteristics of oval cells 
which differentiate via alternative routes into different epithelial lineages. This 
observation indicates that hepatocytes are not narrowed down to generate unipotent 
progenies, but are still equipped to shift into a bipotential precursor compartment. These 
data thus point to a broader plasticity of hepatocytic cell fate determination as expected. 
Studies on the reversibility of hepatoblast-derived differentiation into cholangiocytes and 
hepatocytes in vitro and in vivo support this hypothesis (Fougere-Deschatrette et al., 
2006; Notenboom et al., 2003). Hence, the accessibility of the hepatic MIM model to 
genetic manipulation may provide novel insights into the differentiation repertoire of 
hepatocytes and specification of liver progenitor cells. Furthermore, knowledge about 
the molecular and cellular mechanisms of malignant MIM hepatocytes is both 
conceptually important and relevant for the understanding of hepatocellular 
tumorigenesis. 
 
Etiology and epidemiology of liver cancer 
Hepatocellular carcinoma (HCC) accounts for more than five percent of all cancer cases 
and is the fifth leading cause of cancer mortality worldwide (Kensler et al., 2003). Major 
risk factors well define the etiology of HCC and include viral infection with hepatitis B or 
C, dietary exposure to the fungal toxin aflatoxin or alcohol intoxication. While hepatitis B 
and aflatoxin interaction are the predominant reason for HCC in Asia and Africa, 
hepatitis C and alcohol abuses are the most frequent causative events in Western 
countries. Independent of the carcinogenic insult, chronic hepatitis and cirrhosis 
resulting from inflammation and fibrosis are present in almost eighty percent of HCC 
cases worldwide (Friedman, 2004). Thus, aetiological factors which generate fibrosis 
and cirrhosis with a lower frequency such non-alcoholic fatty liver disorders and non-
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alcoholic steatohepatitits have also a potential role in the development of HCC (Farazi 
and DePinho, 2006). The cirrhotic lesions that commonly proceed dysplastic HCC-like 
foci and nodules already display genomic alterations which further accumulate during 
hepatocarcinogenesis (Lee and Thorgeirsson, 2005). Due to the lack of symptoms in the 
early phase of tumorigenesis and the rapid cancer progression, HCC are most 
frequently recognized at advanced stages. 
 
Molecular mechanisms of HCC 
In the healthy adult liver, quiescent hepatic stellate cells (HSC) represent the major site 
for vitamin A storage in cytoplasmic lipid droplets. During liver injury due to e.g. viral 
infection, HSC get activated to myofibroblasts (MFB) and show cellular remodeling 
required for tissue repair and fibrogenesis (Friedman et al., 2000). These changes in cell 
fate vastly contribute to the establishment of liver fibrosis and subsequent cirrhosis, 
which frequently lead to formation of HCC. Importantly, MFB surround the malignant 
parenchyme intra- and peritumorally upon progression of HCC, indicating their important 
role during cancer progression. The most frequent molecular alterations in human HCC 
include the overexpression and secretion of cytokines such as transforming growth 
factor (TGF)-β (Breuhahn et al., 2006; Rossmanith and Schulte-Hermann, 2001), the 
loss of tumor suppressors such as retinoblastoma, p53, p16INK4A and p14ARF (p19ARF in 
mouse, (Levy et al., 2002; Tannapfel et al., 2001)), the loss of the cell adhesion 
component E-cadherin (Osada et al., 1996), the induction of the Wnt signaling pathway 
through stabilization of nuclear β-catenin (Lee et al., 2006a), and the constitutive 
activation of Stat3 (Signal Transducer and Activator of Transcription; (Levy and Darnell, 
2002)). 
 We previously established a murine hepatocellular model of tumor progression 
based on MMH (Met murine, (Amicone et al., 1997)) and MIM hepatocytes which 
reflects changes leading to a metastatic phenotype through an epithelial to 
mesenchymal transition (EMT, (Eger and Mikulits, 2005; Fischer et al., 2005; Gotzmann 
et al., 2002; Gotzmann et al., 2004)). Such changes in epithelial plasticity during liver 
tumor progression have also been reported in human HCC cell lines and patients 
(Giannelli et al., 2005; Lee et al., 2006b; Lee et al., 2006c). In our cellular models 
employing MMH hepatocytes expressing the cytoplasmic domain of the Met receptor or 
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MIM hepatocytes lacking p19ARF, EMT is caused by the collaboration of hyperactive Ras 
and TGF-β. The gain in malignancy provided by EMT associates with loss of E-cadherin, 
nuclear localization of β-catenin as well as secretion of TGF-β1 which represent 
hallmarks of human HCC progression (Fig. 1). Fibroblastoid hepatocytes that have 
undergone EMT display upregulation of platelet-derived growth factor (PDGF)-A ligand 
and both PDGF receptor subunits along with autocrine PDGF secretion (Gotzmann et 
al., 2006). In accordance with these data, the analysis of human HCCs showed 
enhanced expression of PDGF receptors in cancerous liver tissue compared to the 
adjacent parenchyme indicating a functional implication of PDGF activation in human 
HCC (Chen et al., 2002; Murakami et al., 2005; Tsou et al., 1998; Xu et al., 2001). Loss-
of-function of PDGF signaling upon EMT by the expression of the dominant negative 
(dn) PDGF receptor α causes a strong suppression of tumor formation (Gotzmann et al., 
2006). Intriguingly, this TGF-β-induced PDGF signaling is essentially involved in the 
activation and nuclear localization of β-catenin in hepatocellular EMT since interference 
with PDGF receptor signaling abolishes nuclear β-catenin accumulation in vivo (Fischer 
et al., 2006). This finding is of particular relevance since about 50% of human HCC 
display nuclear accumulation of β-catenin (Buendia, 2000; de La Coste et al., 1998).  
 
 
Heterogeneity and stemness of hepatocellular carcinoma 
Unexpectedly, functional validation of active β-catenin by the constitutive expression of a 
indestructible version of β-catenin revealed suppression of tumor growth and inhibition of 
proliferation in vivo, whereas intervention with β-catenin by the expression of its negative 
regulator Axin causes larger tumor formation (Fischer et al., 2006). Although well known 
target genes of β-catenin such as c-myc and cyclin D1 are expressed, the presence of 
the cell cycle inhibitor p16INK4A is suggested to be responsible for growth arrest. 
Comparable to our findings, nuclear β-catenin accumulation and concomitant expression 
of cyclin D1 and p16INK4A has been observed at the invasive fronts of colorectal 
adenocarcinomas (Bae et al., 2001). 
 Furthermore, active β-catenin protects malignant hepatocytes from anoikis which 
confers the capability to survive in suspension (Fischer et al., 2006). This mechanism 
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represents an important prerequisite for the survival of spreading cells after intravasation 
into the vasculature. Activation of β-catenin in hepatocytes that have undergone TGF-β-
mediated EMT therefore provides characteristics of cell cycle arrested and moreover 
anoikis-resistant cancer cells. The protection against detachment-induced apoptosis 
point to the presence of a cancer stem cell phenotype capable to disseminate which is 
stabilized by β-catenin. Thus, we propose that invasive cancer stem cells result from 
preceding EMT and acquired stemness, both regulated by developmental pathways 
such as TGF-β, PDGF and β-catenin signaling. 
 The route on which hepatocytes progress in malignancy is of particular importance 
for the understanding of HCC. Recent concepts on the tumor stem cell have been 
provided in breast cancer, glioblastoma and acute myeloid leukaemia, which suggest 
that the potential to disseminate are features of cancer stem cells rather than of 
differentiated tumor cells (Pardal et al., 2003). A conceptual extension is provided by 
recent studies which point to the presence of “migrating cancer stem cells” (Brabletz et 
al., 2005). These cells localizing at the invasive front of colorectal carcinoma have 
undergone EMT, a transient and reversible hallmark of disseminating tumor cells. They 
show growth arrest with a concomitant accumulation of the Wnt signaling component β-
catenin, indicating reactivation of developmental programes. With respect to the liver, it 
is still a matter of debate whether hepatic cancer stem cells exist.  
 We hypothesize that different patterns of nuclear β-catenin occur, depending on the 
localization of neoplastic cells in the tumor and correlating with variations in the 
differentiation state of malignant hepatocyte subpopulations. At the inner area of the 
cancerous tissue, neoplastic hepatocytes might have low or are even devoid of nuclear 
β-catenin and exhibit proliferation. In contrast, malignant hepatocytes that have 
undergone EMT at the invasive front might harbor high amounts of nuclear β-catenin 
expression accompanied by growth arrest. We therefore propose a broad differentiation 
repertoire of neoplastic hepatocytes through changes in epithelial plasticity (Fig. 1). The 
fate of this liver tumor stem cell repository might be controlled by the tumor 
microenvironment which on the one hand directs dissemination of liver carcinoma cells 
at the tumor-host interface, and on the other hand induces differentiation of malignant 
cells at the inner area of the tumor. So far, genetic profiling of HCCs and respective 
 52
animal models are promising to molecularly unravel this enigma (Lee and Thorgeirsson, 
2005; Thorgeirsson and Grisham, 2002). Within this context, a subpopulation of HCC 
cells has been identified to show upregulation of particular “stemness genes” in cancer 
cells (Chiba et al., 2006). 
 
Tumor micrenvironment and HCC progression 
We recently investigated the interaction between malignant hepatocytes and activated 
HSC or MFB, the latter representing the main constituents of the tumor-associated 
connective tissue (Pinzani et al., 2005). In addition to MIM hepatocytes, we established 
p19ARF deficient immortalized HSC which show proper expression of characteristic 
marker proteins of activated HSC such as α-smooth muscle actin, glial fibrillary acidic 
protein, pro-collagen I and desmin (Proell et al., 2005). Most notably, these non-
tumorigenic p19ARF null HSC undergo a further transition to MFB in vitro upon treatment 
with TGF-β, and thus provide a suitable cellular tool to analyze the molecular and 
cellular mechanisms involved in liver fibrogenesis. 
 By simultaneous xenografting of these well characterized hepatic cellular models in 
vivo, we showed that paracrine feedback mechanisms governed by activated HSC and 
MFB strongly affect the malignant progression of neoplastic hepatocytes through (i) 
induction of active TGF-β signaling, (ii) nuclear accumulation of β-catenin, and (iii) 
abrogation of E-cadherin mediated cell-to-cell contacts (Mikula et al., 2006). Genetic 
intervention with TGF-β signaling leading to loss of paracrine TGF-β regulation in 
neoplastic hepatocytes confirmed this finding. Hence, these data indicate that the tumor-
progressive TGF-β signaling is induced by paracrine regulation in hepatocytes, and 
molecularly linked to activation of β-catenin. Extrapolation of these findings with recent 
data supports clarification of the scenario, how paracrine and autocrine TGF-β regulation 
of hepatocytes and non-parenchymal liver cells are executed (Fig. 2). Tumor-associated 
macrophages (TAM) comparable to activated Kupffer cells produce TGF-β which 
stimulates activated HSC to complete the transition to MFB. TAM, activated HSC and 
MFB each on its own secrete TGF-β, and positively regulate the progression of 
neoplastic hepatocytes in a paracrine fashion. Hepatocytes proceeding in tumorigenesis 
and displaying an EMT-like, invasive signature produce TGF-β themselves in an 
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autocrine fashion (Gotzmann et al., 2002). Since HCC develops from chronically injured 
liver involving stimulation of Kupffer cells and activation of HSC to MFB, these non-
parenchymal cells are the major source of TGF-β, and thus being predominantly 
responsible for the progression of initiated tumor nodes. Future studies will focus on the 
determination of paracrine regulatory loops between cancerous cells and the host in 
order to unravel the molecular framework of the tumor-host crosstalk in the liver. 
 
Conclusion 
Activation of β-catenin in hepatocytes that have undergone TGF-β mediated EMT 
confers characteristics of cell cycle arrested and anoikis-resistant cancer cells. These 
features point to the presence of a dormant cancer stem cell phenotype in HCC which is 
stabilized by β-catenin and is involved in proximal and distal colonization. The 
quiescence of a subpopulation of liver tumor cells might render them more resistant to 
standard chemotherapy that targets proliferating cells and could therefore be 
responsible for post-operative disease recurrence, as often observed in HCC. These 
aspects implicate important consequences for therapeutic intervention of aggressive 
HCCs, suggesting TGF-β and PDGF as promising targets for anti-cancer drug 
development. 
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Figure Legends 
 
Figure 1: Linear view on the differentiation patterns of neoplastic hepatocytes and the 
heterogeneity of HCCs. Malignant hepatocytes at the tumor center show features of 
epithelial differentiation which is progressively lost towards the tumor-host border. 
Activated myofibroblasts (MFB) mainly presenting the tumor microenvironment provide 
TGF-β in a paracrine mode of regulation. A gradient in the amount of available TGF-β 
induces changes in the epithelial plasticity of neoplastic hepatocytes. Malignant 
hepatocytes close to the tumor-host interface are exposed to bulk TGF-β and undergo 
an EMT which is associated with an autocrine regulation and secretion of TGF-β and 
PDGF. The stroma compartment is boxed in light gray (upper panel), whereas tumor 
cells are trapezoidly boxed in darker gray (lower panel). The dashed line marks the 
tumor-host boundary. 
 
 
Figure 2: The involvement of TGF-β in hepatocellular tumor-stroma interaction. The liver 
tumor microenvironment mainly consists of tumor-associated macrophages (TAM), 
activated hepatic stellate cells (HSC) and myofibroblasts (MFB). TAM secrete TGF-β 
which stimulates HSC to transdifferentiate in MFB. TGF-β produced by TAM and MFB 
induces the malignant progression of hepatocytes by changes in epithelial plasticity. 
Molecular and cellular events corresponding to the non-parenchymal tumor-stroma 
compartment are boxed in light gray (upper panel). Neoplastic hepatocytes undergo an 
EMT in response to TGF-β and are finally endowed with autocrine TGF-β signaling 
(trapezoidly boxed in darker gray, lower panel). Red arrows, paracrine TGF-β regulation; 
winded red arrows, autocrine TGF-β secretion; green to orange shaded arrows; 
activation of HSC to MFB; blue to purple shaded arrows, malignant progression of 
hepatocytes by EMT. The dashed line marks the tumor-host boundary. 
 
 
 
 
 
 61
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TGF-β 
PDGF 
MFB
TGF-
tumor 
body 
tumor-host
border
T
G
F-
β 
a
m
Figure 1: Linear view on the differentiation patterns of neoplastic hepatocytes 
and the heterogeneity of HCCs 
 62
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The involvement of TGF-β in hepatocellular tumor-stroma interaction
neoplastic hepatocytes
metastatic hepatocytes 
TGF-β 
activated HSC
MFBTAM 
TGF-βTGF-β 
liver 
parenchyme 
stroma 
 63
3. ILEI requires oncogenic Ras for the epithelial to mesenchymal 
transition of hepatocytes and liver carcinoma progression 
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Abstract 
In human hepatocellular carcinoma (HCC), epithelial to mesenchymal transition (EMT) 
correlates with aggressiveness of tumors and poor survival. We employed a model of 
EMT based on immortalized p19ARF null hepatocytes (MIM), which display tumor growth 
upon expression of oncogenic Ras and undergo EMT through the synergism of Ras and 
transforming growth factor (TGF)-β. Here we show that the interleukin-related protein 
ILEI, a novel EMT-, tumor- and metastasis-inducing protein, cooperates with oncogenic 
Ras to cause TGF-β-independent EMT. Ras-transformed MIM hepatocytes 
overexpressing ILEI showed cytoplasmic E-cadherin, loss of ZO-1 and induction of α-
smooth muscle actin as well as platelet-derived growth factor (PDGF)/PDGF-R isoforms. 
As shown by dominant-negative PDGF-R expression in these cells, ILEI-induced PDGF 
signaling was required for enhanced cell migration, nuclear accumulation of β-catenin, 
nuclear pY-Stat3 and accelerated growth of lung metastases. In MIM hepatocytes 
expressing the Ras mutant V12-C40, ILEI collaborated with PI3K signaling resulting in 
tumor formation without EMT. Clinically, human HCC samples showed granular or 
cytoplasmic localization of ILEI correlating with well and poorly differentiated tumors, 
respectively. In conclusion, these data indicate that ILEI requires cooperation with 
oncogenic Ras to govern hepatocellular EMT via mechanisms involving PDGF-R/β-
catenin and PDGF-R/Stat3 signaling. 
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Introduction 
Hepatocellular carcinoma (HCC) accounts for 5.5% of all cancer cases worldwide 
(Kensler et al., 2003). Due to the aggressive behavior and the poor prognosis at 
advanced stages, HCC belongs globally to the third leading cause of cancer mortality 
(Bruix et al., 2004). HCC arise through abnormal proliferation and dedifferentiation of 
hepatocytes, caused by hepatitis B or C virus infections, dietary exposure to fungal 
hepatotoxins or alcohol intoxication (Thorgeirsson and Grisham, 2002). Most frequently 
occurring molecular alterations in HCC include the (i) loss of tumor suppressors 
involving p53, pRB, cyclins/cdks or the CDKN2A-encoded proteins p14ARF and p16INK4a 
(El-Serag and Rudolph, 2007; Tannapfel et al., 2001), (ii) loss of the cell-cell adhesion 
protein E-cadherin (Kondoh et al., 2001), (iii) activation of oncoproteins – e.g. receptor 
tyrosine kinases – causing strongly enhanced Erk/MAPK and PI3K signaling (Breuhahn 
et al., 2006), (iv) nuclear accumulation of Wnt/β-catenin (Lee et al., 2006a), and (v) 
aberrant regulation and secretion of cytokines such as transforming growth factor (TGF)-
β (Rossmanith and Schulte-Hermann, 2001). While the knowledge of mechanisms 
involved in HCC is rapidly growing (Herath et al., 2006), the molecular pathogenesis of 
HCC is still poorly understood.  
 Epithelial to mesenchymal transition (EMT) is a developmental event increasingly 
recognized as a central process during cancer progression and metastasis (Grunert et 
al., 2003; Hugo et al., 2007; Thiery and Sleeman, 2006). Multiple molecular mechanisms 
have been identified to induce EMT (Huber et al., 2005), including TGF-β/TGF-βRI 
signaling which collaborates with other signaling effectors to disintegrate tight junctions 
and E-cadherin/β-catenin complexes at cell-cell contacts (Pardali and Moustakas, 2007; 
Thiery and Sleeman, 2006). In human HCC, Laminin-5 and TGF-β1 have been 
described to cooperatively induce EMT at the invasive front of metastatic tumors 
(Giannelli et al., 2005). In addition, signal transducer and activator of transcription 
(Stat)5b collaborates with the hepatitis B oncoprotein HBX to cause EMT and 
invasiveness of HCC (Lee et al., 2006b).  
 To study EMT in hepatocytes, we employed mouse MMH hepatocytes immortalized 
by transgenic expression of cyto-Met (Gotzmann et al., 2002) or a unique model of 
hepatocytes derived from p19ARF null mice. While wildtype mouse hepatocytes cannot 
be expanded due to mitotic inactivity and rapid dedifferentiation, p19ARF deficient MIM1-4 
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hepatocytes proliferate and show characteristics of normal hepatocytes such as 
expression of albumin and the ability to restore the liver after injury (Mikula et al., 2004). 
In both MMH and MIM1-4 hepatocytes, the synergistic action of oncogenic Ras and 
TGF-β signaling induces EMT resulting in a highly malignant, invasive phenotype 
(Gotzmann et al., 2006; Gotzmann et al., 2002). Studies of EMT in MIM hepatocytes by 
employing Ras subeffector mutants revealed that Erk/MAPK signaling is sufficient to 
induce and maintain hepatocellular EMT in cooperation with TGF-β. On the contrary, the 
selective activation of PI3K signaling by expression of V12-C40-Ras showed lack of 
EMT and tumor formation (Fischer et al., 2005). Furthermore, the molecular 
collaboration between oncogenic Ras and TGF-β signaling causes the upregulation of 
platelet-derived growth factor (PDGF)/PDGF-R components which are responsible for 
the nuclear accumulation of β-catenin, the latter representing a hallmark of human HCC 
(Fischer et al., 2007).  
 Recently, expression profiling of polysome-bound mRNA revealed ILEI as a novel 
regulator of EMT (interleukin-like EMT inducer; (Waerner et al., 2006)). In the mammary 
EpH4/EpRas model, overexpression of ILEI causes EMT, tumor growth and metastasis 
upon tail vein injection. Moreover, RNAi-mediated suppression of ILEI prevents EMT 
and metastasis in various murine and human cellular models (Waerner et al., 2006), 
suggesting that ILEI is both necessary and sufficient for these processes. Importantly, 
ILEI localization in cytoplasmic particles was identified as an independent parameter 
predictive for metastasis development and shortened survival of breast cancer patients. 
Cytoplasmic ILEI localization was also observed in nuclear β-catenin-positive tumor cells 
which have undergone EMT at the invasive front of colon carcinomas (Waerner et al., 
2006).  
In this study we analyzed the function of ILEI in MIM hepatocytes and determined, how 
ILEI affects EMT and liver carcinogenesis. We found that ILEI required the cooperation 
with oncogenic Ras to induce and maintain EMT of hepatocytes in a TGF-β-independent 
fashion. Ras/ILEI expressing MIM hepatocytes exhibited upregulation of PDGF/PDGF-R 
associated with Stat3 activation and nuclear accumulation of β-catenin. In human HCC 
samples, cytoplasmic localization of ILEI correlated with poor differentiation and 
prognosis as recently observed in breast cancer patients.
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Results 
 
ILEI is expressed and differentially localized during TGF-β-dependent EMT of 
hepatocytes 
First, we analyzed the expression of endogenous ILEI by immunohistochemistry in 
experimental tumors derived from epithelial hepatocytes expressing oncogenic Ras 
(MIM-R-GFP) and the same cells after EMT upon long-term treatment with TGF-β1, 
resulting in fibroblastoid MIM-RT cells (Fischer et al., 2007). ILEI was hardly detectable 
in normal liver, whereas prominent expression of ILEI was observed in orthotopic tumors 
formed by MIM-R-GFP and MIM-RT cells (Figure 1a). Moderatly differentiated tumors 
generated by epithelial MIM-R-GFP cells showed granular staining of ILEI (Figure 1a). In 
contrast, poorly differentiated tumors generated from fibroblastoid MIM-RT cells 
exhibited cytoplasmic staining of ILEI (Figure 1a). Furthermore, pulmonary metastatic 
colonies of fibroblastoid MIM-RT cells after tail vein injection revealed a mixed 
cytoplasmic and granular localization of ILEI, suggesting a partial reversal of EMT in 
metastatic nodules. From these data we concluded that ILEI is expressed in mouse 
hepatocellular carcinoma but not in normal liver, and is subject to differential localization 
during EMT and cancer progression. 
 
ILEI collaborates with oncogenic Ras to induce and maintain EMT of hepatocytes 
We assessed the role of ILEI in hepatocellular EMT by its stable overexpression in 
immortalitzed MIM1-4 hepatocytes, either alone (MIM1-4-ILEI), together with oncogenic 
Ras (MIM-R-ILEI) or in cooperation with the PI3K-hyperactivating Ras mutant V12-C40 
(MIM-C40-ILEI). Overexpression of total ILEI was verified by Western analysis, showing 
a 2-4 fold increase in all cell types (Figure 1b). 
 ILEI expression on its own or together with V12-C40-Ras did not result in significant 
morphological changes in culture (Figure 2), neither in sparse nor dense monolayers 
(Supplementary Figure S1a). ILEI overexpression in oncogenic Ras-transformed MIM-R-
GFP hepatocytes, however, induced a shift from an epithelial to a fibroblastoid 
morphology, regardless of cell density (Figure 2 and Supplementary Figure S1b), similar 
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to MIM-RT cells having undergone Ras/TGF-β-mediated EMT (Supplementary Figure 
S1b).  
 In line with their epithelial morphology, MIM1-4-ILEI hepatocytes showed plasma 
membrane localization of the epithelial markers ZO-1, E-cadherin and β-catenin similar 
to MIM1-4-GFP control cells, suggesting intact epithelial cell-cell contacts 
(Supplementary Figure S2a). Furthermore, ILEI did neither affect β-actin localization nor 
elevate the mesenchymal marker α-smooth muscle actin (α-SMA) expression 
(Supplementary Figure S2b). In addition, ILEI failed to induce TGF-β/Smad signaling 
since Smad2/Smad3 were entirely cytoplasmic in both MIM1-4-GFP and MIM1-4-ILEI 
cells. Yet, MIM1-4-ILEI cells showed a weak increase of active, nondestructible β-
catenin in nuclei (Supplementary Figure S2a).  
 Coexpression of ILEI and V12-C40-Ras in MIM1-4 cells (MIM-C40-ILEI) resulted in a 
similar marker expression as in MIM1-4-ILEI hepatocytes, i.e. plasma membrane 
localization of ZO-1, E-cadherin, β-catenin and β-actin (Figure 2). MIM-C40-ILEI cells, 
however, displayed elevated nuclear accumulation of β-catenin as compared to MIM1-4-
GFP cells as well as enhanced expression of α-SMA (Supplementary Figure S3). In 
contrast, ILEI plus oncogenic Ras in MIM-R-ILEI cells led to a stable EMT phenotype 
resembling the one observed in MIM-RT cells (Fischer et al., 2005). MIM-R-ILEI cells 
showed a fibroblastoid morphology, strong reduction of ZO-1, cytoplasmic redistribution 
of E-cadherin and relocalization of β-actin from the plasma membrane to stress fibers 
(Figure 2). Furthermore, MIM-R-ILEI cells showed strong nuclear accumulation of β-
catenin (Figure 2) and enhanced expression of α-SMA (Supplementary Figure S3). In 
addition, ILEI induced a partial shift of nuclear to cytoplasmic Smad2/Smad3 localization 
in both MIM-C40-GFP and MIM-R-GFP cells (Supplementary Figure S3), suggesting 
that TGF-β/Smad signaling is inhibited rather than activated. This independence of ILEI 
action from TGF-βR signaling was confirmed by (i) the reduction of secreted TGF-β 
levels by ILEI in all cell types (Supplementary Figure S4), (ii) the inability of the TGFβ-
RI/II kinase inhibitor LY02109761 [Lacher, 2006 #3213] to reverse MIM-R-ILEI cells to 
an epithelial phenotype (data not shown), and (iii) the absence of reporter activities in 
MIM-R-ILEI cells after transfection of Smad2- or Smad3-dependent Luciferase 
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constructs (data not shown). These results demonstrate that ILEI requires oncogenic 
Ras but not TGF-β/Smad signaling to induce and maintain hepatocellular EMT in vitro.  
 
ILEI stimulates upregulation of PDGF-C/PDGF-Rβ and enhances proliferation and 
migration in oncogenic Ras-expressing MIM-R-GFP hepatocytes  
Next, we analyzed the expression of several EMT-specific genes in MIM-R-GFP, MIM-
R-ILEI and MIM-RT cells. Proteins strongly reduced (E-cadherin) or elevated (MMP-9) in 
MIM-RT cells showed weaker down- or upregulation in MIM-R-ILEI cells, respectively 
(Figure 3a). With the exception of Slug, the EMT-inducing transcription factors Twist 
(Yang et al., 2004) and ZEB1/∆-EF1 (Eger et al., 2005) were induced in MIM-R-ILEI 
cells, but surprisingly not in MIM-RT cells (Figure 3a). Since an autocrine loop of 
PDGF/PDGF-R is essential for hepatocellular EMT (Gotzmann et al., 2006) and the 
EMT in EpH4/EpRas cells (Jechlinger et al., 2006), we focused on the effect of 
exogenous ILEI on the expression of different PDGF and PDGF-R isoforms in these 
cells. Interestingly, ILEI induced a strong increase of PDGF-C in MIM1-4-ILEI, MIM-C40-
ILEI or MIM-R-GFP-ILEI cells (Figure 3b). In contrast, the cooperation of ILEI and 
oncogenic Ras in MIM-R-ILEI cells was necessary to induce PDGF-Rβ expression, 
which was very low in MIM-R-GFP cells and undetectable in MIM1-4-GFP and MIM-
C40-GFP hepatocytes expressing or lacking exogenous ILEI. These findings suggest an 
involvement of an autocrine PDGF-C/PDGF-Rβ loop in ILEI-induced EMT of MIM-R-
GFP hepatocytes.  
 We further assessed the effect of exogenous ILEI and PDGF/ PDGF-R signaling on 
the proliferation of parental MIM1-4-GFP and MIM-R-GFP hepatocytes. MIM1-4-GFP 
and MIM-R-GFP cells proliferated with doubling times of 23 hours and 15 hours, 
respectively (Figure 4a and 4b), while exogenous ILEI expression hardly altered 
doubling times (MIM1-4-ILEI, 22 hours; MIM-R-ILEI, 15 hours). Expression of a 
dominant-negative (dn) PDGF-R mutant, however, strongly inhibited proliferation of 
MIM-R-ILEI cells (doubling time of MIM-R-ILEI-dnP cells, 31 hours; Figure 4a). Control 
MIM-R-GFP-dnP hepatocytes expressing the dn PDGF-R showed proliferation kinetics 
comparable to MIM-R-GFP hepatocytes as described recently (data not shown; (Fischer 
et al., 2007)). 
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 In line with the TGF-β-independent function of ILEI in hepatocytes described above, 
MIM1-4-GFP and MIM1-4-ILEI cells underwent proliferation arrest and cell death with 
similar kinetics. TGF-β, however, inhibited early proliferation of MIM1-4-GFP cells 
(during the first 5 cell divisions) more strongly than of MIM1-4-ILEI cells (Figure 4b). 
Therefore, active TGF-β/Smad signaling causes growth arrest and cell death in MIM1-4 
cells lacking or expressing ILEI, except that ILEI may exert early and transient protective 
effects on proliferation. In contrast, Ras-expressing MIM-R-ILEI and MIM-R-GFP-
hepatocytes were both protected from TGF-β-dependent cell cycle arrest and cell death, 
showing exponential proliferation in the presence and absence of TGF-β (Figure 4c; 
data not shown).  
 Another parameter important in EMT is the migratory potential of cells as analyzed 
by Transwell filters. Interestingly, ILEI enhanced the migration not only of MIM-R-GFP 
hepatocytes (as expected from their fibroblastoid phenotype) but also of MIM-C40-GFP 
cells (Figure 4d). This correlates with the fact that MIM-C40-ILEI but not MIM-C40-GFP 
cells are tumorigenic (see below). This ILEI-dependent increase in migratory activity also 
required autocrine PDGF/PDGF-R signaling since its blockade by dn PDGF-R in MIM-R-
ILEI-dnP cells reduced migration to control levels in MIM-R-GFP cells (Figure 4d). From 
these data we concluded that PDGF-R signaling enhanced both cell proliferation and 
migration of hepatocytes that have undergone Ras/ILEI-mediated EMT.  
 
The collaboration of ILEI with oncogenic Ras enhances tumor formation, nuclear 
accumulation of β-catenin and Stat3 tyrosine phosphorylation  
We next investigated the tumorigenicity of ILEI-overexpressing hepatocytes and found 
that exogenous ILEI expression in MIM-1-4-ILEI cells did not cause tumor growth (data 
not shown). Overexpression of ILEI in MIM-R-GFP (MIM-R-ILEI) cells, however, resulted 
in a 4.5-fold increase of tumor size irrespective of the absence or presence of dn PDGF-
R (MIM-R-ILEI-dnP cells; Figure 5a). Tumor growth of control MIM-R-GFP-dnP 
hepatocytes expressing the dn PDGF-R was slightly lower as compared to MIM-R-GFP 
cells (data not shown; (Fischer et al., 2007; Gotzmann et al., 2006)). Interestingly, ILEI 
induced tumorigenicity of MIM-C40-GFP hepatocytes (Figure 5b), which are strictly 
nontumorigenic in the absence of ILEI (Figure 5b, (Fischer et al., 2005)). Remarkably, 
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tumors derived from MIM-C40-ILEI cells showed a delay in tumor formation (detectable 
after 14 days) and a slower growth rate as compared to MIM-R-ILEI-induced tumors but 
reached similar volumes and tumor weights as MIM-R-ILEI tumors (Figure 5c).  
 Immunohistochemical analysis of sections from epithelial MIM-R-GFP- and MIM-R-
GFP-dnP-derived tumors showed that E-cadherin and β-catenin localized at cell 
boundaries of most tumor cells, suggesting the presence of functional cell adhesion 
complexes (Figure 6a). In contrast, tumors generated from MIM-R-ILEI cells showed 
aspects of EMT in vivo such as cytoplasmic E-cadherin, partial loss of plasma 
membrane-localized β-catenin and strong nuclear staining of β-catenin (28% of cells; 
Figure 6a and 6b). Although MIM-R-ILEI and MIM-R-ILEI-dnP-induced tumors resulted 
in comparable volumes (Figure 5a), intervention with PDGF-R signaling in MIM-R-ILEI-
dnP tumors caused reexpression of plasma membrane-localized E-cadherin and 
reduced β-catenin nuclear translocation (Figure 6a). The restoration of E-cadherin 
expression at cell borders of MIM-R-ILEI-dnP cells was also prominent in cell culture 
when compared to MIM-R-ILEI cells (Supplementary Figure S5). In conclusion, ILEI in 
collaboration with Ras induced a similar PDGF-R-dependent EMT phenotype as 
observed in MIM-RT tumors, i.e weak, cytoplasmic E-cadherin staining and 
accumulation of nuclear β-catenin generated by oncogenic Ras plus prolonged TGF-β 
exposure (Supplementary Figure S6; (Fischer et al., 2007).  
 PDGF-R signaling causes tyrosine phosphorylation of Stat3 (pY-Stat3) via Src 
activation (Garcia et al., 2001). Thus, we analyzed the above tumor types for pY-Stat3 
and total Stat3 as well as ILEI expression. Interestingly, MIM-R-ILEI-induced tumors 
(cytoplasmic ILEI staining) showed intense nuclear staining for pY-Stat3 in 27% of cells, 
while only 8% and 11% of cells in MIM-R-GFP and MIM-R-GFP-dnP tumors (both 
granular ILEI staining) showed nuclei positive for pY-Stat3, respectively (Figure 7a and 
7b). As expected, blockade of PDGF-R signaling in MIM-R-ILEI-dnP cells reduced pY-
Stat3 expression to intermediate levels and still showed cytoplasmic ILEI staining 
(Figure 7a), in line with their unaltered tumorigenicity (Figure 5a). In contrast, 
immunohistochemical staining for total Stat3 was similar in all three cell types (Figure 7a 
and 7b). These data show that the Ras/ILEI induced upregulation of PDGF/PDGF-R 
isoforms causes nuclear accumulation of both activated β-catenin and pY-Stat3.  
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ILEI enhances the growth rate of MIM-R-GFP-derived metastatic colonies 
We further asked whether ILEI overexpression enhances metastasis of MIM-R-GFP 
hepatocytes and whether metastasis requires PDGF-R signaling. Thus, we analyzed the 
effect of ILEI overexpression on metastasis and its requirement for PDGF-R signaling in 
MIM-R-GFP cells already causing liver tumors which metastasize to the lung. MIM-R-
GFP, MIM-R-GFP-dnP, MIM-R-ILEI or MIM-R-ILEI-dnP cells were injected into the tail 
vein of SCID mice and further analyzed for lung colonization. While the frequency of 
lung metastases was similar in the four groups of mice, the size of lung metastases was 
slightly enhanced in mice receiving MIM-R-ILEI cells but strongly reduced in those 
injected with MIM-R-ILEI-dnP cells (Supplementary Figure S7a and S7b). MIM-R-ILEI-
dnP cells showed almost no metastases with more than 100 cells while about 40% of 
MIM-R-ILEI-derived metastases contained >100 cells (Supplementary Figure S7b). In 
addition, immunohistochemical staining of sections from these metastases revealed that 
ILEI was predominantly localized in the cytoplasm of MIM-R-GFP and MIM-R-ILEI cells, 
while MIM-R-ILEI-dnP-derived metastases showed also granular areas overlapping with 
nuclei (Supplementary Figure S7c). These data suggest that ILEI-induced PDGF 
signaling increases the growth rate of metastatic colonies from hepatocytes expressing 
oncogenic Ras.  
 
Cytoplasmic localization of ILEI correlates with tumor dedifferentiation in human HCCs 
Recently, it has been described that cytoplasmic expression of ILEI was strongly 
enhanced in metastatic breast carcinomas and tumor-host borders of invasive colon 
carcinomas (Waerner et al., 2006). In an attempt to bridge mouse and human 
hepatocarcinogenesis with respect to the importance of ILEI expression and localization 
for HCC patient prognosis, a tissue array covering 69 human HCC samples was 
immunohistochemically analyzed. ILEI staining intensities were distinguished between 
no, weak or strong staining (Figure 8a). In addition, we further discriminated between 
granular (G) and cytoplasmic staining (C) to evaluate the intracellular localization of ILEI 
(Figure 8a). The important parameter yielding a clear result was postoperative, 
histological grading (pG0 to pG3) which is described to predict good to bad prognosis 
(Edmondson and Steiner, 1954; Zhou et al., 2007). Granular staining was not predictive 
for differentiated HCC with good prognosis. Interestingly, moderately or strongly 
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dedifferentiated tumors (pG2-pG3 grades) were positive for strong cytoplasmic staining 
at a higher frequency (66%) than pG0 (28%). In contrast, weak cytoplasmic ILEI staining 
predicted pG0 (72%) than dedifferentiated tumors (pG2-pG3; 34%). These data suggest 
that strong cytoplasmic ILEI staining can predict poor differentiation and prognosis of 
human HCC. 
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Discussion 
 
We used p19ARF deficient hepatocytes as a physiologically relevant model to analyze the 
function of ILEI during hepatocarcinogenesis. Here, we demonstrate that ILEI strictly 
requires oncogenic Ras to cause TGF-β-independent hepatocellular EMT and tumor 
progression of hepatocytes. In cooperation with hyperactivated PI3K signaling, 
exogenous ILEI expression did not affect the epithelial phenotype of hepatocytes, but 
induced migratory and tumorigenic abilities. ILEI plus oncogenic Ras induced both 
PDGF-C/PDGF-Rβ,  expression which associated with nuclear accumulation of β-catenin 
and pY-Stat3. Using a dominant-negative PDGF-R mutant, we showed that PDGF-R 
signaling is causally involved in Ras/ILEI mediated hepatocellular EMT. Analysis of a 
human HCC tissue array suggested a correlation between dedifferentiation / poor 
prognosis with overexpression of cytoplasmically localized ILEI.  
 Human hepatocarcinogenesis involves ubiquitous, hyperactive Ras signaling as a 
central event caused by epigenetic silencing of Ras inhibitory proteins (e.g. RASSF1A, 
NORE1A; (Calvisi et al., 2006; Macheiner et al., 2006). Accordingly, oncogenic Ras and 
exogenous TGF-β cooperate in normal MIM1-4 hepatocytes to induce and maintain 
EMT, resulting in an invasive, malignant phenotype which associated with autocrine 
TGF-β signaling (Fischer et al., 2005). This study demonstrates that exogenous ILEI 
requires cooperation with oncogenic Ras to cause EMT and hepatocellular carcinoma 
progression in normal MIM1-4 hepatocytes since overexpression of ILEI on its own 
failed to induce changes in morphology, loss of epithelial markers, migration or 
tumorigenicity in MIM1-4 cells (Figures S1a and S2a). In nontumorigenic mammary 
EpH4 cells, however, ILEI alone was sufficient to induce reversible, density-dependent 
EMT, tumor growth and lung metastasis after tail vein injection (Waerner et al., 2006). In 
contrast to the mammary EpH4 model, exogenous ILEI also failed to induce EMT and 
metastasis in the nontumorigenic MIM-C40 cells, but rendered them migratory and 
tumorigenic. These results indicate that oncogenic Ras, which causes constitutive 
hyperactivation of multiple signaling pathways, is strictly required by ILEI to induce EMT 
and tumor progression in hepatocytes. A possible reason why ILEI plus V12-C40-Ras 
caused EMT, tumor and metastasis formation in mammary EpC40-ILEI cells could be 
the fact that these cells show ILEI-enhanced phospho-Erk/MAPK signaling, perhaps 
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cooperating with PI3K hyperactivation to induce EMT. Thus, ILEI probably activates 
endogenous Ras, since the Ras inhibitor L739.749 abolished EMT in mammary EpC40-
ILEI cells (Waerner et al., 2006).  
 A major difference concerning EMT induction by Ras/ILEI versus Ras/TGF-β in both 
hepatocytes and mammary cells was that ILEI-induced EMT neither involved nor 
required autocrine TGF-β secretion. In contrast to mammary cells, MIM1-4-GFP, MIM-
C40-GFP and MIM-R-GFP cells secreted TGF-β at rather high levels which were 2-4-
fold reduced by ILEI expression (Figure S4). In this line, MIM-C40-GFP and MIM-R-GFP 
cells showed nuclear localization of Smad2/3, which was partially shifted to a 
cytoplasmic localization in MIM-C40-ILEI and MIM-R-ILEI cells (Figure S3). These cells 
were also negative for Smad2- and Smad3-dependent activation of luciferase reporter 
constructs (data not shown). Importantly, the TGF-βRI/II kinase inhibitor LY02109761 
failed to revert EMT in MIM-R-ILEI cells (data not shown), suggesting that ILEI-induced 
EMT of Ras expressing hepatocytes occurs independently of TGF-β activation, a finding 
also valid for ILEI-induced EMT in mammary epithelial cells (Waerner et al., 2006).  
 Recently, we showed that TGF-β/Ras-induced hepatocyte EMT led to activation of 
PDGF/PDGF-R signaling which triggers β-catenin to nuclear translocation (Fischer et al., 
2007). Here we demonstrate that Ras/ILEI-induced EMT involved upregulation of PDGF-
C and PDGF-Rβ,  while epithelial MIM-1-4-ILEI and MIM-C40-ILEI cells expressed 
PDGF-C, but not PDGF-Rβ (Figure 3b). This suggests that an autocrine PDGF-
C/PDGF-Rβ loop is important in Ras/ILEI-induced tumor progression, which is supported 
by the finding that transgenic PDGF-C expression in hepatocytes caused fibrosis and 
subsequent HCC (Campbell et al., 2005; Campbell et al., 2007). Bioactive PDGF-CC 
ligand showed high-affinity-binding to PDGF-Rα/α and PDGF-Rα/β dimers, inducing 
similar phospho-Erk1/2 levels as PDGF-AB (Pietras et al., 2003). Our idea that ILEI plus 
Ras-induced autocrine PDGF-C/PDGF-Rβ signaling could activate β-catenin was 
supported by the finding that a dominant-negative PDGF-Rα mutant (dnP) – inactivating 
both PDGF-Rα/α and PDGF-Rα/β dimers – was sufficient to reduce nuclear β-catenin 
levels both in vitro (data not shown) and in vivo (Figure 6). Our observation, however, 
that dnP could not suppress nuclear β-catenin levels of MIM-R-ILEI tumors down to 
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those observed in MIM-R-GFP-derived tumors, suggests additional mechanisms 
contributing to nuclear β-catenin activation.  
 Our finding that Stat3 activation caused by PDGF-R signaling contributes to 
Ras/ILEI-induced hepatocellular EMT is supported by reports that silencing of the Stat3-
inhibitory proteins SOCS1 or SOCS3 by methylation promotes HCC formation by 
stimulating tumor cell proliferation, survival, migration and angiogenesis (Ogata et al., 
2006a; Ogata et al., 2006b; Yang et al., 2007; Yoshikawa et al., 2001). Furthermore, 
activation of Ras and Stat3 by epigenetic inactivation of their endogenous protein 
inhibitors was ubiquitously detected in human HCC (Calvisi et al., 2006). Thus, the 
induction of pY-Stat3 by PDGF signaling during Ras/ILEI-induced EMT could be 
particularly relevant for HCC progression. Whether PDGF-R signaling causes 
phosphorylation of Stat3 via Jak kinases or Src, the latter shown to act as a Stat3 kinase 
downstream of PDGF-R signaling (Silva, 2004), remains to be clarified.  
 In this study, the novel EMT-inducer ILEI is shown to cause EMT and tumor 
progression in normal hepatocytes expressing oncogenic Ras, suggesting that ILEI 
substitutes for tumor-progressive functions of TGF-β signaling in the liver. Since MIM1-4 
hepatocytes are more comparable to normal cells than the murine EpH4 or human 
HMEC mammary epithelial cell models, it was not entirely unexpected that ILEI required 
oncogenic Ras to cause EMT and metastasis in MIM1-4 cells. Yet, ILEI was sufficient for 
EMT induction in the EpH4 model through cooperation with chemokine-dependent 
activation of endogenous Ras. The requirement of Ras/ILEI to cause EMT and tumor 
progression in hepatocytes, together with a putative intracellular mechanism of ILEI 
action, renders ILEI comparable to a rapidly growing number of epithelial polarity/vesicle 
trafficking regulators in Drosophila, which in cooperation with Drosophila Ras cause 
lethal, invasive larval tumors (Giebel and Wodarz, 2006).  
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Materials and Methods 
 
Cell culture 
MIM-R and MIM-C40 hepatocytes were generated by stable retroviral transmission of 
MIM1-4 cells with oncogenic v-Ha-Ras or C40-V12-Ras, respectively (Fischer et al., 
2005). MIM1-4-GFP, MIM-R-GFP and MIM-C40-GFP cells were obtained by stable 
retroviral transmission of MIM1-4, MIM-R and MIM-C40 cells with pMSV-green 
fluorescent protein (GFP), respectively, and subsequent cell sorting. MIM1-4-ILEI, MIM-
R-ILEI, and MIM-C40-ILEI cells were generated by stable transmission of MIM1-4, MIM-
R and MIM-C40 cells with pMSV harboring bicistronic ILEI and GFP (Waerner et al., 
2006), respectively, and subsequent cell sorting. To stably interfere with PDGF 
signaling, MIM-R-ILEI cells were transmitted with pMSV bicistronically expressing the 
dominant-negative (dn) PDGF-receptor α and red fluorescent protein (Fischer et al., 
2007), resulting in MIM-R-ILEI-dnP cells. Details about culture conditions of MIM 
hepatocytes are available as Supplementary Information on the Oncogene website. 
 
Western blot analysis 
Details are available as Supplementary Information on the Oncogene website. 
 
Confocal immunofluorescence microscopy 
Cells were fixed and permeabilized as described earlier (Gotzmann et al., 2006). 
Primary antibodies were used at following dilutions: anti-β-catenin (BD Transduction 
Laboratories (TL), Lexington, UK), 1:100; anti-active-β-catenin (Upstate, Lake Placid, 
USA), 1:100; anti-E-cadherin (TL), 1:100; anti-α-smooth muscle actin (Dako, 
Carpinteria, USA), 1:100; anti-Smad2/3 (TL), 1:100; anti-ZO-1 (Zymed, San Francisco, 
USA), 1:100; phalloidin (Molecular Probes, Eugene, USA), 1:40. Nuclei were visualized 
using To-PRO3 (Invitrogen, Carlsbad, USA) or DAPI (Roche, Basel, Switzerland) at 
dilutions of 1:10.000 and 1:1.000, respectively. 
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Tumor formation in vivo 
1 x 106 cells in 50 µl Ringer solution were either orthotopically transplanted into the liver 
by injection into the spleen or subcutaneously injected into immunodeficient CB-17 SCID 
recipient mice as described (Fischer et al., 2007; Mikula et al., 2004). Tumor volume and 
weight were determined after subcutaneous tumor formation as recently described 
(Fischer et al., 2007). Tumor incidences were equal to 100%, i.e. all injected malignant 
hepatocytes gave rise to experimental tumors. All experiments were performed twice 
using three mice per cell type and carried out according to the Austrian guidelines for 
animal care and protection. 
 
Immunohistochemistry 
Paraffin-embedded sections of tumor tissues were stained with the following antibodies: 
anti-β-catenin (Transduction Laboratories (TL), Lexington, UK), 1:100; anti-active β-
catenin (Upstate, Lake Placid, USA), 1:100; anti-Stat3 (Cell Signaling, Beverly, USA), 
1:100; anti-phospho-Stat3 (Cell Signaling, Beverly, USA), 1:100; anti-E-cadherin (TL), 
1:100; anti-ILEI (Waerner et al., 2006), 1:100. More details are available as 
Supplementary Information on the Oncogene website.  
 
Reverse transcriptase polymerase chain reaction (RT-PCR) 
Extraction of poly(A)+-mRNA and cDNA synthesis were performed as recently described 
(Gotzmann et al., 2006). The PCR amplification products were analyzed by agarose gel 
electrophoresis. Details about primer sequences are available as Supplementary 
Information on the Oncogene website. 
 
Proliferation kinetics 
1 x 105 cells were seeded in triplicate and the number of cells in the corresponding cell 
populations was determined periodically in a multichannel cell analyzer (CASY; Schärfe 
Systems, Reutlingen, Germany). Cumulative cell numbers were generated from the 
absolute cell counts and their calculated dilution factors (Gotzmann et al., 2002). 
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Transwell assay 
Details are available as Supplementary Information on the Oncogene website. 
 
Tissue array 
Tissue array (ORIDIS Biomed, Graz, Austria) contained paraffin-embedded specimens 
of tumors and adjacent normal tissue collected from 69 female and male HCC patients 
which were surgically removed between 1995 and 2004. Protocols of the retrospective 
analyses were approved by the local institutional review board of the Medical University 
of Graz. All histological specimens were reviewed for histological type and grade. Core 
biopsies with diameter of 0.6 mm were taken from each donor paraffin block. 4 µm thick 
sections of each tumor and adjacent tissue were arrayed in triplicate. After antigen 
retrieval in sodium-citrate buffer (pH 6.0), the anti-ILEI antibody (Waerner et al., 2006) 
was used at a dilution of 1:300. More details are available as Supplementary Information 
on the Oncogene website.  
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Figure legends 
 
Figure 1: ILEI expression in moderately or poorly differentiated experimental liver 
tumors and in ILEI-transduced hepatocytes. Epithelial MIM-R-GFP hepatocytes, or MIM-
RT cells that have undergone EMT, were orthotopically transplanted into the spleen or 
injected by tail vein. Liver tumors were collected after 20 days and processed for 
histology and immunohistochemistry. (a) Sections from wild type BALB/c livers (control), 
MIM-R-GFP and MIM-RT generated liver tumors, and lung metastases induced after tail 
vein injection of MIM-RT cells were stained with Hematoxylin & Eosin (H&E) or 
immunohistochemically stained with anti-ILEI antibody. Scale bar represents 50 µm. 
Insets show staining of tumor sections at 4-fold higher magnification to reveal 
endogenous ILEI localization. (b) ILEI-overexpressing MIM1-4-ILEI, MIM-C40-ILEI and 
MIM-R-ILEI cells or empty vector expressing MIM1-4-GFP, MIM-C40-GFP and MIM-R-
GFP cells were analyzed by immunoblotting using anti-ILEI and anti-β-actin antibodies. 
The expression of β-actin is shown as a loading control. 
 
Figure 2: ILEI causes the disassembly of epithelial junctions, cytoskeletal reorganization 
and β-catenin activation in cooperation with oncogenic Ras. Phase contrast images of 
MIM-C40-GFP, MIM-C40-ILEI, MIM-R-GFP and MIM-R-ILEI cells are shown in the top 
panels (bar: 50 µm). The lower panels show confocal immunofluorescence images of 
these cell types after staining with specific antibodies against ZO-1, E-cadherin (E-cad), 
total β-catenin (total β-cat), activated, nondestructible β-catenin (nondestr. β-cat) and 
phalloidin to visualize β-actin. Blue-green staining: DNA. Bar in confocal images: 15 µm. 
Insets (green border): Cells marked by white dots are shown without DNA staining to 
better visualize cytoplasmic versus nuclear staining of activated β-catenin (green 
asteriks in main panel mark DNA staining). 
 
Figure 3: Expression of EMT markers and PDGF / PDGF-R isoforms in hepatocytes 
before and after ILEI-overexpression. (a) Expression levels of transcripts for E-cadherin, 
the E-cadherin-repressing transcription factors Slug, Twist and ZEB-1, and the matrix 
metalloproteinase MMP-9 in MIM-R-GFP, MIM-R-ILEI and MIM-RT cells (positive EMT 
control), as determined by linear semi-quantitative RT-PCR. (b) Individual transcript 
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levels of three PDGF isoforms (PDGF-A, -B, -C) and two PDGF-receptor isoforms 
(PDGF-R and PDGF-Rβ) were analyzed by linear semi-quantitative RT-PCR in MIM1-
4-GFP-, MIM1-4-ILEI-, MIM-C40-GFP, MIM-C40-ILEI-, MIM-R-GFP- and MIM-R-ILEI- 
cells. Constitutive levels of rhoA mRNA are shown as a loading control.  
 
Figure 4: ILEI modulates migratory behavior of hepatocytes but has little effect on 
proliferation. (a-c) Proliferation kinetics were determined by cumulative cell numbers. (a) 
Proliferation kinetics of untreated MIM-R-GFP, MIM-R-ILEI and MIM-R-ILEI-dnP cells. 
(b) Proliferation kinetics of MIM1-4-GFP and MIM1-4-ILEI cells as well as (c) MIM-R-
GFP and MIM-R-ILEI cells during treatment with TGF-β1 (1 ng/ml). (d) Control cells 
(MIM-C40-GFP and MIM-R-GFP), ILEI-overexpressing cells (MIM-C40-ILEI and MIM-R-
ILEI) and ILEI-overexpressing MIM-R-GFP cells harboring a dominant-negative PDGF-
R (MIM-R-ILEI-dnP) after transmigration through Transwell filters. Migrated cells were 
visualized by Hoechst staining under UV-light and counted (numbers represent 
transmigrated cell numbers per standard microscopic field). Error bars denote S.E.M.  
 
Figure 5: ILEI enhances tumor formation in synergy with oncogenic Ras and induces 
tumorigenicity in nontumorigenic hepatocytes expressing the PI3K-hyperactivating Ras 
mutant V12-C40. Tumors were generated in SCID mice by subcutaneous injection of 
MIM-R-GFP (a, white bars), MIM-R-ILEI-dnP (a, dark gray bars), MIM-R-ILEI cells (a, 
black bars) and MIM-C40-ILEI (b, light gray bars). Control MIM-C40-GFP hepatocytes 
(b, hatched bars) failed to form tumors. (a, b) Kinetics of tumor formation as determined 
by calculation of tumor volumes. (c) Weights of tumor tissues collected after 20 days 
(MIM-R-GFP, white bar; MIM-R-ILEI, black bar; MIM-R-ILEI-dnP, dark gray bar) or 49 
days (MIM-C40-ILEI, light gray bar). Statistically significant weight differences 
(p<0.0005) between MIM-R-GFP and MIM-R-ILEI tumors are indicated with ***. (a-c) 
One representative experiment out of three is shown. Error bars denote S.E.M.  
 
Figure 6: Ras plus ILEI expression increases nuclear β-catenin levels in vivo which 
requires PDGF-R signaling. (a) Experimental tumors obtained after subcutaneous 
injection of MIM-R-GFP, MIM-R-GFP-dnP, MIM-R-ILEI or MIM-R-ILEI-dnP cells into 
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SCID mice were collected after 20 days and processed for histology (H&E) and 
immunohistochemistry using anti-E-cadherin (E-cad), anti-β-catenin (total β-cat) or anti-
activated, nondestructible β-catenin (nondestr. β-cat) antibodies. Bar, 50 µm. Insets 
show staining of tumor sections at 5-fold higher magnification to reveal details of E-
cadherin localization at cell membranes and nuclear β-catenin. (b) Quantitative 
evaluation of cells for nuclei expressing activated, nondestructible β-catenin. Error bars 
depict S.E.M. from three independent experiments.  
 
Figure 7: The cooperation of ILEI and Ras activates Stat3 in a PDGF-dependent 
fashion. (a) Subcutaneous tumors were generated in SCID mice, collected after 20 days 
and processed for immunohistochemistry, employing anti-ILEI, anti-phospho-Stat3 (pY-
Stat3) and anti-total Stat3 (total Stat3) antibodies for staining. Bar: 50 µm. Insets: 5-fold 
enlarged images to reveal details in granular versus cytoplasmic ILEI staining and 
nuclear pY-Stat3 staining. (b) Quantitative evaluation of cell nuclei positive for tyrosine-
phosphorylated Stat3 (pY-Stat3; gray bars) and total Stat3 (black bars). Statistically 
significant differences (p<0.05) in expression of pY-Stat3 are indicated with *.  
 
Figure 8: Intensity and pattern of ILEI expression predicts tumor dedifferentiation and 
prognosis of human HCCs. A tissue array containing 69 human HCC samples and 
respective control liver tissues was immunohistochemically stained with anti-ILEI 
antibody. (a) Shown are representative examples for no (negative), weak or strong 
granular and cytoplasmic ILEI staining of the HCC tissue array. Bar: 200 µm. (b) The 
intensity of granular (gran; left panel) and cytoplasmic (cyto; right panel) ILEI staining 
(weak including negative or strong) was correlated with postoperative histological 
grading (pG) of the HCC in the array ranging from well-differentiated (pG1) to 
moderately (pG2) and poorly dedifferentiated HCCs (pG3). pG2 and pG3 were grouped 
together because of low sample numbers for pG3. While strong granular staining slightly 
correlated with more differentiated HCC, strong cytoplasmic staining correlated with 
poorly differentiated HCC and thus bad prognosis. The comparison of the tumor grading 
distribution between the groups cytoplasmic weak and cytoplasmic strong was 
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significant (p<0.05) showing a higher percentage of pG1 and pG2-3 tumors in the group 
cytoplasmic strong than in group cytoplasmic weak. 
 
Supplementary Materials and Methods 
 
Cell culture 
Immortalized p19ARF null MIM1-4 hepatocytes were grown in RPMI 1640, 10% fetal calf 
serum (FCS), 40 ng/ml recombinant human TGF-αSigma, St.Louis, USA), 30 ng/ml 
human IGF-II (Sigma, St. Louis, USA), 1.4 nM Insulin (Sigma, St. Louis, USA) and 
antibiotics as previously described (Mikula et al., 2004). MIM1-4-GFP, MIM1-4-ILEI and 
MIM-C40-GFP hepatocytes were propagated in RPMI 1640, 10% FCS and growth 
factors as described for MIM1-4 hepatocytes, whereas all other cell types were cultured 
in RPMI 1640 and 10% FCS without additional growth factors. MIM-RT cells were 
obtained by prolonged TGF-β1 treatment (1 ng/ml) of MIM-R(-GFP) hepatocytes as 
previously described (Fischer et al., 2005). Fibroblastoid MIM-RT and MIM-R-ILEI cells 
were grown on tissue culture plastic, whereas epithelial hepatocytes required rat tail 
collagen-coated culture dishes (Gotzmann et al., 2002). All cells were kept at 37°C and 
5% CO2, and routinely screened for the absence of mycoplasma. The TGF-βRI/II kinase 
inhibitor LY02109761 (a kind gift of Eli Lilly and Company, Indianapolis, USA; (Lacher et 
al., 2006)) was used at a concentration of 1 µM. 
 
Western blot analysis 
Immunoblotting was performed as previously described (Gotzmann et al., 2002). The 
primary antibodies were used at the dilutions: anti-ILEI (1:1.000; (Waerner et al., 2006)); 
anti-β-actin (Sigma, St.Louis, USA), 1:2.500. Horseradish peroxidase-conjugated 
secondary antibodies (Calbiochem, LaJolla, USA) were used at dilutions of 1:10.000. 
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Immunohistochemistry 
Biotinylated secondary antibodies were employed and visualization was performed with 
the vectastain ABC kit using diaminobenzidine as substrate (Vector Laboratories, 
Burlingame, USA). 
 
Reverse transcriptase polymerase chain reaction (RT-PCR) 
The following forward and reverse primer were used for the specific amplification, 
respectively: Slug, 5’-CATTTCAACGCCTCCAAGAAGC-3’ and 5’-
GAAGCAGCCAGGGTCTGGAG-3’; Twist, 5’-GCTCCTCTGCTCTACCCTCC-3’ and 5’-
TGCTAGTGGGACGCGGACAT-3’. All other primers used have been previously 
described (Gotzmann et al., 2006; Gotzmann et al., 2002).  
 
Enzyme-linked immunosorbent assay (ELISA) 
For determination of latent TGF-β1 secretion into the medium, cells were grown in 
serum-free RPMI containing 10 mM Hepes and antibiotics for 24 hours. Aliquots of cell 
culture supernatants were used directly for ELISAs according to the instructions of the 
manufacturer (Bender MedSystems, Vienna, Austria). All assays were performed in 
triplicate. Values were normalized to background measurements from respective growth 
media and calculated on the basis of a TGF-β1 standard curve. Values of secreted 
proteins are expressed per 1 x 106 cells and per ml supernatant. 
 
Colonization of tumor cells in vivo after tail vein injection 
5 x 104 cells in 25 µl Ringer solution were injected into the tail vein of immunodeficient 
CB-17 SCID recipient mice. Xenografted mice were sacrified after 14 days. 
Subsequently, the lung was removed and subjected to histological and 
immunohistochemical analyses. All experiments were performed twice in triplicate and 
carried out according to the Austrian guidelines for animal care and protection. 
 
Transwell assay 
4 x 104 cells were seeded on Transwell filters with a pore size of 8 µm (Corning Costar, 
Cambridge) and incubated for 24 hours. Visualization of migrated cells through 
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Transwell filters using Hoechst 33258 has been recently outlined (Fischer et al., 2007). 
Migrated cells were quantified by counting per microscopic field at a ten-fold 
magnification. Assays for each condition were performed twice in triplicate. 
 
Tissue array 
Secondary antibody was employed and visualization was performed with the ChemMate 
Envision Kit (DAKO, Carpinteria, CA, USA). Two independent researcher (C.L. and 
M.M.) evaluated the immunostaining on triplicate tissues by using weak and strong 
staining intensities of ILEI-positive areas, which covered at least 50% of the total tumor 
area. Comparison of the tumor grading distribution between the groups cytoplasmic 
weak and cytoplasmic strong was done by the Jonckheere-Terpstra test in SAS (SAS 
9.2 , SAS Institute Inc., Cary, NC, USA). 
 
 
Supplementary Figure legends 
 
Supplementary Figure S1 Morphology of ILEI-overexpressing hepatocytes. Shown are 
phase contrast images from hepatocyte populations, seeded either at low (top 
subpanels; sparse) or high density (bottom subpanels; dense) on tissue culture plates. 
(a) MIM1-4 hepatocytes expressing GFP (MIM1-4-GFP), ILEI (MIM1-4-ILEI), the Ras 
mutant V12-C40 plus GFP (MIM-C40-GFP) or V12-C40-Ras in combination with ILEI 
(MIM-C40-ILEI). (b) MIM1-4 hepatocytes expressing oncogenic Ras plus GFP (MIM-R-
GFP), Ras plus ILEI (MIM-R-ILEI), or Ras plus ILEI and dn PDGF-Rα (MIM-R-ILEI-dnP). 
MIM-RT cells representing MIM-R-GFP hepatocytes after prolonged TGF-β1 treatment 
are shown as controls. Bar, 50 µm.  
 
Supplementary Figure S2 Overexpression of ILEI on its own in hepatocytes fails to 
induce changes in their epithelial phenotype. Confocal immunofluorescence images of 
MIM1-4 hepatocytes expressing either GFP (MIM1-4-GFP) or ILEI (MIM1-4-ILEI) are 
shown. (a) For expression and localization of epithelial cell markers, cells were stained 
with specific antibodies against ZO-1, E-cadherin (E-cad), total β-catenin (total β-cat) 
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and activated, nondestructible β−catenin (nondestr. β-cat). Insets: Cells are shown 
without DNA staining to visualize nuclear versus cytoplasmic staining of activated, 
nondestructible β-catenin. (b) To monitor β-actin localization and α-smooth muscle actin 
(α-SMA), cells were stained with phalloidin and anti-α-SMA antibody, respectively. 
Nuclear or cytoplasmic localization of Smad2 and Smad3 were detected using an 
antibody staining both Smads. Bar, 15 µm.  
 
Supplementary Figure S3 ILEI causes TGF-β-independent upregulation of α-SMA and 
reduces nuclear Smad2/Smad3 in hepatocytes coexpressing oncogenic Ras or V12-
C40-Ras. Shown are confocal immunofluorescence images of MIM-C40-GFP, MIM-C40-
ILEI, MIM-R-GFP and MIM-R-ILEI cells after staining with anti--SMA and anti-Smad2/3 
antibodies. Insets in lower panels show Smad localization without nuclear staining to 
better visualize nuclear Smad in the GFP control cells and the partial shift of Smad2/3 
into the cytoplasm upon ILEI expression. Bar, 15 µm. 
 
Supplementary Figure S4 ILEI does not stimulate but reduce TGF-β1 secretion of MIM 
hepatocytes coexpressing oncogenic Ras or the Ras mutant V12-C40. Cell culture 
supernatants from the cell types indicated (see legend to Figure S1) were harvested and 
analyzed by ELISA to determine the amount of latent TGF-β1 secretion after 
normalization to cell numbers.  
 
Supplementary Figure S5 Expression of dominant negative PDGF-R (dnP) restores E-
cadherin localization at cell boundaries of MIM-R-ILEI cells. Confocal 
immunofluorescence images of MIM-R-GFP, MIM-R-GFP-dnP, MIM-R-ILEI and MIM-R-
ILEI-dnP after staining with specific antibodies against E-cadherin (E-cad) or total β-
catenin (total β-cat) are shown. 
 
Supplementary Figure S6 The cooperation of Ras and TGF-β in MIM-RT-induced 
tumors show EMT in vivo. Tumor tissues were collected 20 days after subcutaneous 
injection of epithelial MIM-R-GFP or fibroblastoid MIM-RT cells into SCID mice. (a) 
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Shown are images of tumor sections after H&E staining (top) and immunohistochemical 
staining employing anti-E-cadherin (E-cad), anti-total β-catenin (total β-cat) and anti-
activated, nondestructible β-catenin (nondestr. β-cat). Bar: 50 µm. Insets show staining 
of tumor sections at 5-fold higher magnification to reveal E-cadherin localization (plasma 
membrane staining in MIM-R-GFP cells changing to weak cytoplasmic staining in MIM-
RT cells) and increasing nuclear localization of total and activated β-catenin in 
fibroblastoid MIM-RT cells. (b) Quantitative evaluation of cells harboring nuclei stained 
for activated, nondestructible β-catenin.  
 
Supplementary Figure S7 ILEI enhances metastasis formation in a PDGF-dependent 
fashion. 5 x 104 of MIM-R-GFP, MIM-R-ILEI, MIM-R-GFP-dnP or MIM-R-ILEI-dnP cells 
were each injected into the tail vein of SCID mice and lung colonization was evaluated 
14 days after cell injection. (a) Micrographs of lungs bearing MIM-R-GFP- and larger 
MIM-R-ILEI-derived metastases. (b) H&E-stained lung sections from the four types of 
metatstatic lungs were evaluated for cell numbers per metastasis (grouped into <50 
cells, 50-100 cells and >100 cells) in all metastases from 3 lungs resected. MIM-R-ILEI 
cells generated slightly increased lung metastases whereas those derived from MIM-R-
ILEI-dnP cells were strongly reduced. In accordance with recently published data 
(Jechlinger et al., 2006), control MIM-R-GFP-dnP cells showed a metastatic colonization 
into the lung with even smaller colonies as compared to those derived from MIM-R-GFP 
cells. (c) Shown are images of metastatic lung sections after H&E staining (top insets, 
outline of metastases indicated by dotted lines) and after ILEI-staining (main panel; 
bottom insets with black frames showing 4-fold magnification). While MIM-R-GFP- and 
MIM-R-ILEI-induced metastases show general cytoplasmic staining (including nuclei), 
MIM-R-ILEI-dnP-derived metastases show diffuse or granular (arrows) staining of the 
nuclear area only (outlines of nuclei indicated by dotted lines).  
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Abstract 
Epithelial to mesenchymal transition (EMT) is a crucial process in development and 
plays an important role during tumor formation and metastasis. One of the most 
important events involved in EMT is the loss of the adherens junction protein E-cadherin, 
which is caused by the cooperation of transforming growth factor beta (TGFβ)1 and  
oncogenic Ras signaling. Here we show that the signal transducer and activator of 
transcription (Stat) 3 is activated by Tyr705 phosphorylation in collaboration with TGFβ 
and oncogenic Ras siganling during EMT formation. To study the role of StatT3 in 
hepatocellular EMT, we generated p19ARF deficient hepatocytes expressing oncogenic 
Ras in combination with either constitutive active or dominant negative versions of Stat3. 
Interstingly the gain-of-function of Stat3 revealed a decreased tumor formation together 
with a diminished metastatic colonization of the lungs. In contrast, loss–of-function of 
Stat3 resulted in the opposite effect revealing a tumor suppressive role of Stat3 in liver 
carcinogenesis. Expression profiling studies of these cell lines revealed a Stat3-
dependent upregulation of c-jun, an important factor in the development of liver tumors, 
and the induction of matrix-metalloproteinase (MMP) 3, which has been reported to play 
a crucial role in the establishment of EMT. These results point to an important role of 
Stat3 together with oncogenic Ras in liver tumor progression. 
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Introduction 
 
Hepatocellular carcinoma (HCC) is the fifth most common cancerous disease worldwide 
and the third common cause of mortality due to its aggressive progression (Kensler, 
Qian et al. 2003; Bruix et al. 2004; El-Serag, Gilger et al. 2006). The major risk factors 
for this disease are viral infections like hepatitis B and C, alcohol abuse and fungal 
toxins like Aflatoxin B1 (Thorgeirsson and Grisham 2002). Beside all these environmental 
factors, genetic and epigenetic alterations play an important role in the formation of 
HCC. Among them are the dysregulation of key signal transducers and known tumor-
suppressor genes such as for example β-catenin, p16, p53 and E-cadherin (Toyosaka, 
Okamoto et al. 1996; el-Assal, Yamanoi et al. 1997; Lee, Park et al. 2006; Llovet 2006). 
A major event in hepatocellular tumor progression is the epithelial-to-mesenchymal 
transition (EMT), which leads to the dissociation of cell-cell contacts followed by a 
dramatic phenotypical change of the tumor cells (Yang, Mani et al. 2004; Hugo, Ackland 
et al. 2007). Involved in the transformation of epithelial cells to mesenchymal, 
fibroblastoid cells is the upregulation of transcriptional repressors of E-cadherin such as 
Snail or Zeb1 (Hanahan and Weinberg 2000). The loss of E-cadherin associates with a 
higher migratory potential of cells and metastasis formation (Thiery 2002). Studies on 
EMT in human liver cancer revealed novel factors involved in this process among them 
signal transducer and activator of transcription (Stat) 5b (Lee, Man et al. 2006) and 
Laminin-5 (Bergamini, Sgarra et al. 2007). 
Especially in HCC the constitutive activation of Stat molecules might play a major role in 
neoplastic formation (Calo et al. 2003). Among the 7 different members of Stat 
molecules, Stat3 is known to serve as an oncogene (Bromberg et al., 2000). Currently 3 
different isoforms of Stat3 termed, Stat3α, Stat3β and Stat3γ (Akira et al. 1994; Hevehan 
et al. 2002) are described and their functions are poorly understood. Full length Stat3, 
also known as Stat3α, consists of 6 different domains, among them the coiled-coil 
domain, necessary for interactions with other proteins, as for example CBP/p300, 
followed by the DNA-binding domain, the SH2-domain and the transactivation domain, 
which is truncated in Stat3β (Dewilde et al. 2008). After binding of cytokines to their 
cognate receptors, receptor dimerization occurs followed by an phosphorylation step of 
the non-covalently bound Janus kinases (Jak) (Wheadon et al. 1999; Darnell 2002). 
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Activated Jak phosphorylates the receptor and therefore expose SH2-binding sites for 
cytosolic Stat molecules (Darnell 2002). The now bound Stat molecules dimerize and 
translocate into the nucleus where they start to activate several target genes (Aaronson 
and Horvath 2002).  
Another important factor involved in the formation of HCC due to its ability to cause EMT 
is transforming growth factor (TGF)β  (Rossmanith 2002) which is a multifunctional  
peptide with many different functions such as control of proliferation and differentiation of 
normal tissue (Sporn et al. 1986; Rossmanith et al., 2001). After binding of one of the 
three TGFβ ligands to the TGFβRII, a heterodimeric formation of TGFβRI and TGFβRII 
takes place (Massague 2000), which causes the phosphorylation of the regulatory 
subunit of TGFβRI followed by the activation of the receptor associated SMAD proteins 
Smad2 and Smad3 (Massague 2000; Heldin, Eriksson et al. 2002; Pardali and 
Moustakas 2007). In more than 50% of human HCC, cancerous cells secrete TGFβ and 
therefore cause EMT and uncontrolled growth of the surrounding cells. The established 
autocrine loop of secreted TGFβ influences the migratory potential of neoplastic 
hepatocytes. In recent studies it has been shown that the collaboration of TGFβ1 and 
Laminin-5 causes hepatocellular EMT (Lee et al., 2006) and tumor progression in an α3-
integrin-dependent fashion (Fuchs et al., 2008; Tang et al., 2008). Studies on breast 
cancer stem cells revealed an important role of TGFβ in cooperation with Stat3-
signalling (Tang et al., 2008). 
In this study we addressed the role of Stat3 during the Ras-mediated EMT and tumor 
progression of hepatocytes. In particular, constitutive Stat3 activates in collaboration 
with oncogenic Ras associated with a strong tumor suppression which might depend on 
p19ARF deficiency. The cooperation of Stat3 and Ras further showed an increase of c-jun 
and MMP-3, which might play a role in the acquisition of an EMT phenotype. 
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Results 
 
Stat3 is activated during EMT 
StatT3 is known to be involved in tumor progression, however the role of Stat3 in 
hepatocellular EMT is an unresolved issue. Therefore we first analyzed the expression 
of Stat3 by immunohistochemistry of subcutaneous tumors derived from epithelial 
hepatocytes expressing oncogenic H-Ras (MIM-R) and the same cells after treatment 
with TGFβ (MIM-RT) over 14 days. Activated Stat3 (pStat3) was hardly detectable in the 
control liver tissue and in the MIM-R tumors, whereas in the tumors derived from MIM-
RT cells a strong expression of pStat3 was detectable (Figure 1A). The expression of 
total Stat3 was not altered in all three analyzed tumor samples. To verify this finding, a 
Western-Blot containing MIM-R and MIM-RT cell lysates was carried out which revealed 
phosphorylated Stat3 in MIM-RT but less in MIM-R (Figure 1B). These data show that 
Stat3 is activated by Tyr705 phosphorylation during hepatocellular EMT. 
 
 
Expression of constitutive active (ca) and dominant negative (dn) Stat3α and β versions 
in Ras-transformed hepatocytes 
For a better understanding of the role of Stat3 in tumor progression we retrovirally 
transmitted MIM-R hepatocytes, which were already expressing oncogenic Ras with 
several Stat3 constructs (Figure 2A). Further, as a control, a wt construct of Stat3 and a 
version lacking the transactivation domain and the tyrosine responsible for the 
phosphorylation and therefore for the activation of Stat3 were also transformed in MIM-R 
cells (Figure 2A). For both ca versions of Stat3, the Stat3α and β isoforms carried each 
two point mutations in their SH2-domain, A662N664C, leading to the formation of 
disulfide bridges causing a constitutive dimerization of the Stat3 monomers and 
therefore a permanent activity. The dn forms were constructed by exchanging the 
aminoacid tyrosine 705 into a phenylalanine resulting in a blockade of the 
phosphorylation of the amino acid and therefore in a permanent inactive form of both 
Stat3α and Stat3β isoforms (Besser et al. 1999). All Stat3-transfected hepatocytes 
showed a more than 85% GFP-purity and were stably diploid (Table 1). 
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For studies on the DNA binding activity of all Stat3 versions, we performed an 
electrophoretic mobility shift assay (EMSA) either in the presence interleukin (IL)-6, or in 
the presence of an inhibitor of Stat3 expression, the Jak inhibitor (Figure 2B). A 
difference in the strength of DNA binding was observed between the Stat3α and the 
Stat3β isoform which was already shown in previous reports (Dewilde et al. 2008). 
Usually the expression-ratio of Stat3β in comparison to Stat3α is much lower, but during 
inflammation the amount of both isoforms is almost equal. After overexpression of 
Stat3β this factor is constitutively tyrosine-phosphorylated and can then bind DNA and 
promote transcription due to an extended half-life of the phosphorylated dimer (Dewilde, 
et al., 2008). For a better understanding of the EMSA experiment, the signals were 
quantitative analyzed (see Figure 2C).  
Regarding these results, all used constructs seem to work in the predicted way and 
cause either upregulation or downregulation of Stat3 in our hepatic MIM cell system. 
Worth mentioning is the stronger DNA binding activity of the Stat3β isoform compared to 
the other versions (Figure 2B).  
 
 
Expression of constitutive active (ca) Stat3 in Ras-transformed hepatocytes reveals 
reduced tumor formation  
We next examined the tumorigenic role of Stat3 in combination with oncogenic Ras. Ca 
Stat3α, and in particular, Stat3β overexpression caused smaller tumors than the control 
tumors generated by MIM-R cells alone (Figure 3A). The volume of Stat3β tumors were 
4-fold reduced compared to MIM-R-control tumors. The greatest tumorigenecity showed 
the dnStat3β tumors compared with all others. The difference in size was 2-fold higher to 
the MIM-R and 6-fold higher to the caStat3β tumors leading to the conclusion that Stat3 
in combination with oncogenic Ras rather has a tumor suppressive role. Also very 
interesting was the finding that the ∆S683Stat3 version without transactivating domain 
also showed an increase in tumor size compared to MIM-R control tumors (Figure 3B). 
In contrast control wtStat3 version showed only very small tumors.  These results 
suggest a tumor suppressive role of Stat3 in combination with oncogenic Ras in 
hepatocytes lacking p19ARF.  
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Diminished metastatic colonization of hepatocytes co-expressing ca Stat3 and 
oncogenic Ras  
For further analysis of Stat3, we investigated the metastatic role of caStat3 and dnStat3. 
For this reason we injected the hepatocytes transmitted with oncogenic H-Ras and 
either Stat3α or Stat3β into the tail vein of SCID mice and analyzed the colonization of 
the lung with these cells. The results showed a tumor-suppressive role of caStat3 in 
metastasis formation and therefore a reduced metastatic behaviour due to the 
decreased amount of lung colonies. As depicted in Figure 4, metastasis produced by 
caStat3α/β led to a 2- to 4-fold decrase of colony formation and also to small secondary 
tumors in the respiratory organ compared with the MIM-R cell as a control. Expression of 
dnStat3 versions in hepatocytes resulted in a 2-fold decrease in the amount of 
secondary colonies and large metastasis of dnStat3α. WtStat3 and ∆S683Stat3 cells 
showed also a decreased amount of metastasis in the lung. Colonies dervied from the 
overexpression of wtStat3 resulted in small metastasis and for the expression of 
∆S683Stat3, the secondary lung colonies were large. Therefore these data suggest a 
metastasis-suppressive role of Stat3 in the p19ARF deficient model of hepatocellular 
carcinoma progression. 
 
Upregulation of c-jun and of matrix metalloprotease 3 (MMP3) in hepatocytes co-
expressing ca Stat3 and oncogenic Ras 
For further investigation we performed by expression profiling to identify genes, which 
are upregulated in response to the different expression mutant Stat3 versions. For this 
purpose we used a commercial array covering 99 genes involved in Stat-signalling (see 
Figure 5). Among the influenced genes, c-jun, a gene, which in combination with c-fos 
constitutes the AP-1 complex (Rahmsdorf 1996), showed a 6- to 10-fold upregulation in 
MIM-RT and caStat3α compared to the expression level in the control MIM-R-cells. Also 
the downregualtion of c-jun in the dnStat3-cells is worth mentioning and therefore c-jun 
might play a role in tumor suppression of caStat3 expressing malignant hepatocytes 
(see Figure 5).   
Another upregulated gene dependend on Stat3 was the matrix-metalloproteinase 
(MMP)-3, which is known to play a role in epithelial-to-mesenchymal transition (Nagase, 
Meng et al. 1999) due to its opportunity to degrade extracellular matrices (Lijnen, 
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Maquoi et al. 2002). The upregulation of MMP-3 was between 30-fold in MIM-RT and 
90-fold in MIM-R-caStat3β-cells compared to the expression level in the MIM-R cells. 
Therefore caStat3 might play a role in tumor initiation and progression due to the 
upregulated c-jun and MMP-3. These data obtained by expression profiling further 
suggest the Stat3-dependent upregulation of c-jun and MMP-3 and might play a 
prominent role during hepatocellular carcinoma progression. 
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Discussion 
 
In this paper we focused on the role of activated Stat3 and its ability to modulate EMT 
and hepatic tumor progression. Stat3 in combination with a p19ARF deficiency showed a 
tumor suppressive role in a cellular EMT model employing H-Ras transformation. These 
tumors showed a decreased tumor formation compared with the control tumors. We 
could also show an increased activation of at least two target genes of Stat3, namely c-
Jun and MMP-3, during EMT progression. However further studies are required to 
identify the mechanisms underlying the tumor-suppressive role of Stat3. 
Recent findings have shown that Stat3 is also activated in other tumors than in 
hepatocellular cancerogenesis. For example a role of Stat3 was detected in primary 
breast tumors, where inhibition of Stat signaling downstream of Src or Janus kinases 
showed an abrogated constitutive Stat3 DNA binding, inhibited cell proliferation and 
induced apoptosis (Bowman, et al., 2000; Garcia and Jove, 1998). Also an increased 
expression of Stat3 in multiple myeloma (Catlett-Falcone, et al., 1999), head and neck 
cancer (Grandis, et al., 1998), lung cancer (Fernandes, et al., 1999) and lymphoma 
(Lund, et al., 1997; Lund, et al., 1999; Nielsen, et al., 1997; Sun, et al., 1998; Weber-
Nordt, et al., 1996; Zhang, et al., 1996) implied a tumor-promoting role of Stat3 
(Bowman, et al., 2000)  
In this study we used a cellular model of p19ARF null hepatocytes for analyzing the role of 
Stat3 in tumorigenesis. Expression of caStat3a or caStat3b nor their dominant negative 
versions on its own resulted in an undetectable phenotype with respect to EMT 
formation and tumorigenesis. Thus we focused on the cooperative role of Stat3 and 
oncogenic H-Ras. CaStat3 overexpressing cells in combination with oncogenic H-Ras 
were injected in mice causing a decreased tumor formation compared to control cells 
without activated Stat3. However, experiments done with the MMH-D3 hepatocytic cell 
line showed contrary effects resulting in an increase of tumor formation under the 
influence of activated Stat3 (caStat3, data not shown). Noteworthy, MMH-D3 
hepatocytes have been immortalized by transgenic cyto-Met expression (Amicone et al., 
1987), and express p19ARF at levels comparable to primary hepatocytes (data not 
shown). Therefore these results revealed a tumor progressive role of Stat3 in a p19ARF 
background, which was lost upon expression in a p19ARF-positive genetic background. 
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Next we studied the necessity and sufficiency of Stat3 for EMT in these cells. We could 
show that neither caStat3α/β nor dnStat3α/β modulated the TGFβ-dependent EMT in 
vitro (data not shown).  
To have a more detailed insight into the ability of Stat3 to cause EMT in hepatocytes, 
also the role of other Stat family members should be analyzed in this process. A 
compensatory role of other Stat-family members such as Stat1 or Stat5, could explain 
the suppressive role of caStat3 in p19ARF deficient hepatocytes due to the fact that both 
Stat molecules are also described as growth inhibitors and activator of apoptosis 
(Bromberg, 2000).  
The expression of caStat3 and dnStat3 showed an unexpected effect in our 
investigations and revealed a tumor suppressive role of Stat3 in a p19ARF mouse 
backgorund. This tumor suppressive role of Stat3 depends on the combination with 
oncogenic H-Ras in a p19ARF null background. Similar results were found with c-Fos, a 
factor involved in the AP-1 complex and JunB (Eferl, 2003). Therefore, this study 
describes a novel tumor suppressive role of Stat3 in hepatocellular tumor progression. 
The upregulation of MMP3 and c-Jun in hepatocytes overexpressing ca Stat3 isoforms 
in collaboration with H-Ras is the matter for further experiments helping to 
mechanistically understand the tumor suppressive role of Stat3. Both factors are 
important in generating an EMT phenotype and therefore seem to play a role in tumor 
progression rather than in tumor suppression. Due to the fact that cells which undergo 
an EMT show a higher migratory potential than epithelial cells, this effect can be 
combined with increased tumor formation. The upregulation of c-jun and MMP-3 
together with caStat3 in combination goes along with a decreased tumor formation and 
colonization of adjacent organs. All these results represent the basis for further 
questions which will be addressed in future investigations.  
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Materials and methods 
 
Cell culture 
MIM-R hepatocytes were generated by stable retroviral transmission of immortalized 
p19ARF null hepatocytes (MIM1-4) with a construct bicistronically expressing oncogenic 
v-Ha-Ras and green fluorescent protein (GFP) as outlined recently (Fischer et al. 2005). 
In order to study the role of Stat3 in hepatocellular EMT, we used MIM-R hepatocytes 
expressing either wild-type Stat3 (MIM-R-wtStat3), a C-terminally truncated version of 
Stat3 (MIM-R-Stat3∆C683), the constitutive active mutants of Stat3alpha or beta (MIM-
R-caStat3α or -caStat3β) or the dominant negative mutants of Stat3alpha or beta (MIM-
R-dnStat3α or -dnStat3β) after retroviral transmission (Cockerham and Zeng 1996; 
Reya, Duncan et al. 2003). All cells were grown in RPMI 1640 plus 10% fetal calf serum 
and antibiotics at 37°C and 5% CO2, and were routinely screened for the absence of 
mycoplasma. Treatment of epithelial cells, such as MIM-R with TGF-β1 over 14 days 
resulted in stable fibroblastoid cell lines, termed MIM-RT. For long-term treatment of 
cells, TGF-β1 was added at a concentration of 1 ng/ml. Fibroblastoid cells were grown 
on plastic, whereas epithelial cells required culture dishes coated 
with rat tail collagen, prepared as described (Gotzmann, Fischer et al. 2006). For 
stimulation of the cells, interleukin (IL)-6 (R&D Systems, McKinley Place NE, USA) was 
added at a concentration of 20ng/ml and for the investigation of theDNA-binding activity, 
a Jak inhibitor (Calbiochem, LaJolla, CA, USA) was added at a concentration of 1µM. 
GFP-expression and the ploidy of the cells was measured by FACS analysis and 
described in Table 1. 
 
Western blot analysis 
The preparation of cellular extracts, separation of proteins by sodiumdodecylsulfate–
polyacrylamide gel electrophoresis and immunoblotting were carried out as described 
recently (Gotzmann, Huber et al. 2002). The protein extract from 1x105 cells per sample 
was loaded onto gels, and immunological detection of proteins was performed with the 
SuperSignal detection system (Pierce Chemical Company, Rockford, IL, USA). The 
following primary antibodies were used: anti-phospho-Stat3 (Cell Signaling, Beverly, MA, 
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USA), 1:1000; anti-Stat3 (Cell Signaling, Beverly, MA, US). Secondary antibodies 
(Calbiochem, LaJolla, CA, USA) were used at dilutions of 1:10 000. 
 
Electophoretic mobility shift assay (EMSA) 
Culture dishes of adherent cells were rinsed twice with ice-cold PBS. Cells were scraped 
off and pelleted by centrifugation (1 min, 1000g). Pellets were mixed with two times of 
the volume with whole cell extract buffer (20 mM Hepes, pH 7.9; 20% Glycerol; 50 mM 
KCl; 1 mM EDTA; 1 mM DTT (Sigma); 400 mM NaCl; 5µg/ml Leupeptin (Boehringer 
Mannheim); 0.2 units/ml Aprotinin (Bayer); 1 mM PMSF (Boehringer Mannheim); 5 mM 
Na3VO4; 10 mM NaF; 5 mM b-glycerophosphate) and subjected to freeze-thaw cycles 
which were repeated 4 times. Extracts were centrifuged at 4°C for 20 minutes, and the 
supernatant was subjected to EMSAs. Oligo (m67 5´-dGATTTCCCGTAAATCAT-3´) was 
annealed at high equimolar concentration in a 200 µl reaction with annealing buffer (10x 
= 0.625x PCR Buffer II (Roche); 9.4 mM (MgCl2) by heating up to 95°C and a slow cool 
down to room temperature. Annealed oligos were then diluted to 2.5 µM. Extracts (20 µg 
protein) from cell extracts were incubated with 0.5 – 1 µl hot probe (8,000 cpm/fmol) in a 
20 µl reaction volume containing DNA-binding buffer (10 mM Tris; 1 mM DTT; 0.2 mM 
PMSF; 0.1 mM EDTA; 5% Glycerol; 50 mM NaCl; 0.1% NP4O), 2 µl BSA (10µg/µl in 20 
mM KPO4, 50 mM NaCl, 0.1 mM EDTA, 5% glycerol) and 2 µl Poly dI-dC (1 µg/µl; 
Roche Diagnostics) for 5 - 15 minutes at room temperature before loading on the gel. 
Complexes were separated on a non-denaturating 4% acrylamide (BIO-RAD; 
acrylamide:bis-acrylamide = 29:1). TBE was used as running buffer at 200V for about 3 
hours. The gel was transferred onto filter paper (Whatman Chromatography Paper), 
dried on a vacuum gel dryer at 80°C for two hours and x-ray films (Kodak Biomax MR) 
were exposed at –80°C. 
 
RNA isolation and expression profiling 
RNA was isolated from cells using RNeasy kit (Qiagen, Valencia, CA) according to the 
manufacturer’s protocol. Quality of the RNA was analyzed using the Agilent Bioanalyzer 
(Agilent Technologies). Expression profiling, including the preparation of cRNA and 
hybridization to JAK / STAT Signaling Pathway Oligo GEArrays® (Super Array, 
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Bioscience Corperation) was done according to the manufacturer’s protocol. Data 
analysis was performed using ImageQuant™ TL (Molecular Dynamics). 
 
 
Tumor formation in vivo 
Cells of the respective cell type were detached from the tissue culture plate, washed 
with PBS, and resuspended in Ringer solution. Subsequently, 1x106 cells in 100 µl 
Ringer solution were subcutaneously injected into immunodeficient SCID/BALB/c 
recipient mice. Tumor formation was periodically measured by palpation, and the tumor 
size was determined using a vernier caliper. Tumor volume was calculated from tumor 
size using the formula diameter x diameter x length/2, and the tumor weight in milligram 
was determined as described recently (Gotzmann, Huber et al. 2002). Tumor incidences 
were equal to 100%, which means that all injected cell populations gave rise to 
experimental tumors. All experiments were performed in triplicate and carried out 
according to the Austrian guidelines for animal care and protection. 
 
Intrasplenic transplantation of hepatocytes 
1x106 of cultured cells resuspended in 20 µl Ringer solution were injected into the 
spleen of SCID mice. All experiments were performed in duplicate and carried out 
according to the Austrian guidelines for animal care and protection. 
 
Immunohistochemistry of experimental tumors 
SCID mice were sacrificed and the obtained tumors, livers or lungs were fixed in 4% 
phosphate-buffered formaldehyde overnight at 4°C (Mikula, Fuchs et al. 2004). Four µm 
thick sections were stained with hematoxylin and eosin for standard microscopy. For 
immunohistochemical analyses, paraffin-embedded sections (4 µm) were treated with 
citric acid buffer (0,01M, pH 6.0) before staining with the following antibodies: anti-
phospho-Stat3 (Tyr705) (Cell Signaling, Beverly, MA, USA), 1:1000; anti-Stat3 (Cell 
Signaling, Beverly, MA, US), 1:100. Corresponding biotinylated secondary antibodies 
were employed and visualization was performed with the vectastain ABC kit using 
diaminobenzidine as substrate (Vector Laboratories, Burlingame, USA). 
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Figure legends 
 
Figure 1: Stat3 is activated during EMT. (A) Epithelial MIM-R hepatocytes and 
corresponding fibroblastoid MIM-RT cells that have undergone EMT were each 
transplanted into the spleen of severe combined immunodeficiency (SCID) mice. The 
resulting experimental liver tumors were subjected to immunohistochemical analysis by 
employing an anti-pStat3 antibody (Tyr705, Cell Signaling technology, USA) which 
revealed a prominent activation of Stat3 in MIM-RT derived liver tumors. Insets show 
staining of tumor sections at 4-fold magnification. Nuclear pStat3 is indicated by arrows. 
(B) Epithelial MIM-R hepatocytes and fibroblastoid MIM-RT cells were processed for 
Western blot analysis. MIM-RT hepatocytes showed Tyr705 phosphorylation of Stat3 
after long-term stimulation with TGF-β.  
 
Figure 2: Expression of constitutive active (ca) and dominant negative (dn) Stat3 
versions in Ras-transformed hepatocytes. (A) Schematic representation of the Stat3 
constructs stably co-expressed in Ras-transformed hepatocytes. (B) Overexpressing 
Stat3 cells were stimulated with 20 ng/ml IL/6 prior to harvesting. Whole cell extracts 
were analyzed by electromobility shift assays (EMSA) using the M67 site containing a 
Stat3 consensus sequence. (C) Quantitative evaluation of (B). DNA binding could be 
diminished after incubation with 1 µM pan-JAK inhibitor in the parental cell line (Tang, et 
al.) and in cells overexpressing dn Stat3 versions but not after expression of either wt or 
ca Stat3.  
 
Figure 3: Expression of constitutive active (ca) Stat3 in Ras-transformed hepatocytes 
reveals reduced tumor formation. Tumor volumes after subcutaneous injection of 
hepatocytes overexpressing oncogenic H-Ras and mutant Stat3 versions into 
immunodeficient SCID mice. (A) Reduced tumor formation was observed in Ras-
transformed cells expressing ca Stat3 mutants. In contrast, larger tumor formation was 
associated with expression of dn Stat3β. (B) Similar effects on tumor growth were 
observed with wtStat3 and Stat3∆C683. 
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Figure 4: Diminished metastatic colonization of hepatocytes co-expressing ca Stat3 and 
oncogenic Ras. Malignant hepatocytes showed metastatic colonization after tail vein 
injection. Hematoxylin/eosin staining of lung tissue sections revealed differences in 
number and size of metastatic colonies after expression of various Stat3 mutants in Ras-
expressing hepatocytes. (B) Metastatic colonies were counted according to their size. 
Malignant hepatocytes expressing ca Stat3 showed a diminished metastatic potential. 
 
Figure 5: Upregulation of c-jun and of matrix metalloprotease 3 (MMP3) in hepatocytes 
co-expressing ca Stat3 and oncogenic Ras. (A) Expression profiling of malignant 
hepatocytes after introduction of various Stat3 mutant versions revealed differential gene 
expression. Red encircled is the c-jun expression, black circles correspond to MMP-3 
expression. (B) Evaluation of c-jun as well as MMP3 compared to MIM-R hepatocytes. 
Both genes were upregulated in cells that have undergone EMT (RT) and in cells that 
express ca Stat3.  
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Table 1: GFP positivity and polyploidy of used cell lines 
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Figure 1: Stat3 is activated during EMT 
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Figure 2: Expression of constitutive active (ca) and dominant negative (dn) Stat3 
versions in Ras-transfromed hepatocytes 
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Figure 3: Expression of constitutive active Stat3 in Ras-transfromed hepetaocytes 
reveals reduced tumor formation 
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Figure 4: Diminished metastatic colonization of hepatocytes co-expressing ca 
Stat3 and oncogenic H-Ras 
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